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Abstract 
The importance of cognitive decline in Parkinson’s disease (PD), which eventually 
progresses to dementia (PD-D) in the majority of surviving patients, has been widely 
recognised during the last decade. PD-D is associated with a twofold increase in mortality, 
increased caregiver strain and increased healthcare costs. Thus, early and correct 
identification of the PD patients with a risk of dementia is a challenging problem of 
neurology, which has led to the suggestion of various markers of cognitive decline in PD. 
If validated, these markers would offer the opportunity for disease modification and 
therapeutic intervention at a critical early stage of the illness, when the viable neuronal 
population is greater.  
The focus of this thesis was to assess how various factors - quantitative 
electroencephalography (qEEG) changes, genetics, deep brain stimulation (DBS), 
olfactory function, etc. – may be related with the risk of cognitive decline in PD patients. 
We performed four clinical studies with various design. These studies included PD 
patients who were dementia-free on inclusion, and control participants. 
Principal findings are the following: (1) increase of global median relative power theta 
(4–8 Hz), executive and working memory dysfunction are independent prognostic 
markers of severe cognitive decline in PD patients over a period of 3 years. (2) DBS of the 
subthalamic nuclei in a group of PD patients with mean age 63.2 years, in comparison with 
a group of younger patients (52.9 years), causes higher incidence of psychiatric events 
over 2 years of observation. However, these events were transient and did not outweigh 
the benefits of surgery. (3) Worsening of verbal fluency performance is an early cognitive 
outcome of DBS of the subthalamic nuclei in PD patients. (4) Among early appearing non-
motor signs of Parkinson’s disease, alteration of olfaction but not EEG spectrum correlates 
with motor function. (5) A composite score approach seems to be a realistic goal  in the 
search for biomarkers of severe cognitive decline. 
  
Keywords:  Parkinson’s disease (PD), dementia, biomarkers, quantitative 
electroencephalography (qEEG), deep brain stimulation (DBS) 
 4 
 
V. V. Cozac (Kozak) 2018 
Acknowledgements  
I would like to acknowledge all those who have ensured that this project was 
successful: the participants and their relatives and the research team. Special thanks go 
to my supervisors, Prof. Peter Fuhr and Prof. Ute Gschwandtner for their support and 
guidance during these years, and to my medical Alma mater supervisors: Member of the 
Academy of Sciences Prof. Stanislav A. Groppa, Prof. Ion V. Moldovanu, Prof. Oleg C. Pascal 
and Ass. Prof. Lilia A. Rotaru: for introducing me to the world of clinical neurology. 
I am deeply thankful to PD Dr. Johannes Sarnthein that he kindly agreed to serve as 
external expert on my doctoral committee.  
The analysis of my dataset would not have been possible without the contribution of 
my colleagues and Alumni from the Universitätsspital Basel and the Parkinson Team 
Basel: Jan Guy Bogaarts, Matthias Briel, Menorca Chaturvedi, Mirjam Christ-Crain, Michael 
M. Ehrensperger, Ivana Handabaka, Martin Hardmeier, Florian Hatz, Antonia Meyer, 
Rainer Nehring, Karolina Nowak, Anne Dorothée Roesch, Manuela Rytz, Stephan Rüegg, 
Ethan Taub, Bianca Auschra, Antje Welge-Lüssen. 
 Collaborators on this project have included the team of Prof. Volker Roth from the 
Department of Mathematics and Computer Science of the University of Basel, the team of 
Prof. Andreas Urs Monsch from the Memory Clinic and University Center for Medicine of 
Aging of the Felix Platter Hospital, and the team of Prof. Thomas Gasser from the Hertie 
Institute for Clinical Brain Research of the University Hospital of Tübingen.  
I am grateful to the patients and clinical and research staff who took part in this 
research. 
My son Yaroslav, my wife Rodika, my parents, my sisters and my friends all provided 
invaluable support during my research.  
Lastly, this project was supported by the Swiss National Science Foundation and the 
Camelia Botnar Foundation.  
 
 
 
 
 
 
 
 
 5 
 
V. V. Cozac (Kozak) 2018 
Contents 
Capitol Page No 
Abstract 3 
Aknowledgements 4 
Abbreviations 7 
Chapter 1. Introduction 9 
The burden of dementia in Parkinson’s disease 9 
Deep brain stimulation and cognitive decline in Parkinson’s disease 9 
Aims of the thesis 10 
Outlines of the thesis 10 
List of publications within the thesis 11 
Chapter 2. Parkinson’s disease and dementia: outlines 13 
Clinical features of Parkinson’s disease  13 
Epidemiology of Parkinson’s disease 13 
Aetiology of Parkinson’s disease 14 
Pathophysiology of Parkinson’s disease 17 
Cognitive decline in Parkinson’s disease 18 
Dementia in Parkinson’s disease 18 
Pathophysiology of dementia in Parkinson’s disease 20 
Deep brain stimulation and dementia in Parkinson’s disease 21 
Biomarkers of dementia in Parkinson’s disease 22 
Management of cognitive decline in Parkinson’s disease 24 
Chapter 3. Genetic and EEG markers of dementia in Parkinson’s disease 26 
Genetic markers  26 
Quantitative EEG markers 27 
Spectral analysis 28 
Functional connectivity analysis 30 
Reliability of the qEEG analysis 31 
Test-retest effect 32 
Influence of dopamine-replacement therapy on qEEG parameters 32 
Chapter 4. Study I: Quantitative EEG markers of dementia in Parkinson’s disease – a 
systematic review 
34 
Methods of literature search 34 
Analysis of the findings 35 
Spectral characteristics of cognitive states in Parkinson’s disease 37 
Global power spectra 37 
Topographic distribution of power spectra 39 
Correlation of power spectra with cognitive assessment tools 40 
Hazard of conversion to dementia in Parkinson’s disease 42 
Brain functional connectivity and cognitive states in Parkinson’s disease 42 
Chapter 5. Study II: Three-years observation of a cohort of patients with Parkinson’s 
disease 
44 
Methods 44 
Enrollment of the patients 44 
Standard protocol approvals, registrations, and patient consents 44 
Neurological assessment 44 
Cognitive assessment 44 
Neurophysiological assessment 45 
Blood sampling and genotyping 45 
Statistics 46 
Results 47 
Chapter 6. Study III: Effects of deep brain stimulation in Parkinson’s disease on 
psychiatric parameters with regard to age of the patients 
55 
 6 
 
V. V. Cozac (Kozak) 2018 
Methods 55 
Patients’ selection 55 
Operative procedure  56 
Analyses of the cases 56 
Statistical analysis 56 
Results 57 
Chapter 7. Study IV: Effects of deep brain stimulation in Parkinson’s disease on 
cognitive parameters with regard to age of the patients 
59 
Methods 59 
Patients’ selection 59 
Neuropsychological and neuropsychiatric assessment 60 
Statistical analyses 61 
Results 61 
Chapter 8. Study V: Olfactory deficits and quantitative EEG in patients with 
Parkinson’s disease 
64 
Methods 64 
Patients selection 64 
Assessment of the olfactory function 65 
EEG processing    65 
Cognitive tests 65 
Statistics 65 
Results 66 
9. Integrated discussions and conclusions 69 
Discussions 69 
Methodological considerations: strengths and limitations 73 
Conclusions 75 
References 78 
Supplements 94 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations 
 AD = Alzheimer’s disease 
 APOE = apolipoprotein E 
 ATP13A2 = probable cation-transporting ATPase 13A2 
 ATR = alpha/theta ratio 
 7 
 
V. V. Cozac (Kozak) 2018 
 AUC = area under the curve 
 BDI-II = Beck Depression Inventory, revision II 
 BPRS = Brief Psychiatric Rating Scale 
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Chapter 1. Introduction 
The burden of dementia in Parkinson’s disease 
Parkinson’s disease (PD) is a degenerative disease of the central nervous system, which 
has motor and non-motor features (Capriotti and Terzakis, 2016).  Historically PD was 
considered a disease, which affects mainly motor functions of the patients; however, 
nowadays it is aknowledged, that non-motor symptoms of PD also have a dramatical 
impact on the quality of life and disability of the patients (Khoo et al., 2013). The 
importance of cognitive decline in PD, which eventually progresses to dementia in the 
majority of surviving patients, has been widely recognised during the last decade 
(Aarsland et al., 2017; Aarsland and Kurz, 2010; Kim et al., 2009; Riedel et al., 2008). 
Dementia in PD (PD-D) is associated with a twofold increase in mortality (Levy et al., 
2002), increased caregiver strain (Aarsland et al., 2007) and increased healthcare costs 
(Vossius et al., 2011). Thus, early and correct identification of the PD patients with a risk 
of dementia is a challenging problem of neurology, which has led to the suggestion of 
various markers of cognitive decline in PD (Mollenhauer et al., 2014). Currently, genetics 
and quantitative electroencephalography (qEEG) are gaining research interest as a source 
for potential risk markers of PD-D (Aarsland et al., 2017). There have been reports that 
slowing of EEG frequency some and genetic variants are associated with cognitive decline 
in PD (discussed in Chapter 3). 
Deep brain stimulation and cognitive decline in Parkinson’s disease 
In recent years, it has been largely acknowledged that deep brain stimulation (DBS) — 
a neurosurgical implantation of an electrical pulse generator with electrodes projected to 
specific targets in the brain — can alleviate motor symptoms of PD, though the exact 
mechanisms of therapeutic effects of DBS are still not fully resolved (Garcia et al., 2013). 
Cognitive impairment in PD is a limiting factor for the selection of candidates for DBS, also 
evidence has been accumulating that DBS itself can result in worsening of cognitive 
performance (Massano and Garett, 2012). Some research groups suggested that such 
worsening may be owing to a “microlesion” of the brain tissue, produced by the passage 
of the electrodes during implantation (Maltete et al., 2008). Other researchers have 
suggested that post-DBS cognitive decline may be related to the age of the patient (DeLong 
et al., 2014). Further studies and critical analyses regarding the relation of DBS and 
cognitive decline in PD are warranted to provide much needed clinical evidence and guide 
future health care policy. 
Aims of the thesis 
The general aim of the thesis was to investigate the value of genetic and qEEG markers 
to identify PD patients with a risk of dementia. Within this main research focus, we also 
investigated the influence of DBS and advancing age on cognitive decline in PD. The list of 
studies carried out within this research is provided below. 
Study I (systematic review): review of the literature concerning qEEG markers of 
cognitive decline. A search for peer-reviewed original studies in the period 2000 – 2015 
was performed. We planned to compare the obtained data with the findings from our 
study II. 
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Study II (observational longitudinal (cohort) study): investigation of a three-years 
cohort of patients with PD with regard to finding clinical and neurophysiological markers 
of cognitive decline. The hypothesis was that slowing of EEG (identified by mathematical 
processing and calculation of global frequency power) precedes clinical onset of severe 
cognitive decline in PD patients. 
Study III (observational case-control study): investigation of the early cognitive 
outcomes of DBS in PD patients. We checked for the decrease in cognitive task 
performance in patients with PD after six months after DBS to the subthalamic nuclei 
(STN), and compared these patients to non-operated PD patients. The hypothesis was 
that DBS is associated with a decrease of verbal fluency cognitive task performance. 
Study IV (retrospective cohort (and case-control) study): investigation of the late 
outcomes of DBS in PD patients with regard to the age at operation. I retrospectively 
checked the two-years’ clinical and neuropsychiatric outcomes in a group of PD patients 
with DBS to the STN (STN-DBS) with regard to the age of the participants. The hypothesis 
was that age has no negative effects on the neurological outcomes of DBS. 
Study V (cross-sectional study): investigation of the olfactory function with regard to 
qEEG features and cognitive function of PD patients. I checked olfactory function and its 
relation to motor and qEEG parameters in patients with PD and healthy controls. The 
hypothesis was that olfactory decline in PD correlates with clinical and qEEG 
parameters.  
Outlines of the thesis 
Following this introduction, the thesis begins with a chapter on background (Chapter 
2), in which we provide an overview on most important aetiological and 
pathophysiological features of PD, cognitive decline in the context of PD, and markers of 
such decline.  In Chapter 3 we give a detailed overview on known genetic and qEEG 
markers of dementia and cognitive decline in PD. The following chapters - from 4 to 9 - 
contain the core methodological contributions of this thesis. Chapter 4 deals with the 
results of the systematic review of peer-reviewed literature on qEEG markers of PD 
related cognitive impairment. Chapter 5 presents the results of my core study – 
observation of patients with PD by means of genetic and qEEG analyses with PD-D as 
primary outcome. Chapters 6-8 present the results of the substudies, focused on 
investigation the relation of DBS, age and olfaction with cognitive fucntions and qEEG 
changes. Chapter 9 contains integrated discussions and conclusions of this thesis. 
List of publications within the thesis 
A. Full journal articles  
    [1]1 Cozac, V.V., Chaturvedi, M., Hatz, F., Meyer, A., Fuhr, P., Gschwandtner, U. (2016). Increase 
of EEG spectral theta power indicates higher risk of the development of severe cognitive decline 
in Parkinson’s disease after 3 years. Frontiers in Aging Neuroscience. 8:284. DOI: 
10.3389/fnagi.2016.00284;  
                                                          
1 With permission of respective publishing offices the following publications are included into this thesis. 
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[2]1 Cozac, V.V., Gschwandtner, U., Hatz, F., Hardmeier, M., Rüegg, S., Fuhr, P. (2016). 
Quantitative EEG and Cognitive Decline in Parkinson's Disease. Parkinson's Disease 1-14, Article 
ID 9060649. DOI: 10.1155/2016/9060649;  
 [3]1 Cozac, V.V., Ehrensperger, M.M., Gschwandtner, U., Hatz, F., Meyer, A., Monsch, A.U., 
Schuepbach, M., Taub, E., Fuhr, P. (2016). Older Candidates for Subthalamic Deep Brain 
Stimulation in Parkinson's Disease Have a Higher Incidence of Psychiatric Serious Adverse Events. 
Frontiers in Aging Neuroscience. 8;8:132. DOI: 10.3389/fnagi.2016.00132;  
 [4]1 Cozac, V.V., Schwarz, N., Bousleiman, H., Chaturvedi, M., Ehrensperger, M.M., 
Gschwandtner, U., Hatz, F., Meyer, A., Monsch, A.U., Taub, E., Fuhr, P. (2015). The Verbal Fluency 
Decline After Deep Brain Stimulation in Parkinson's Disease: Is There an Influence of Age? 
Movement Disorders Clinical Practice. 3: 1. 48-52. DOI: 10.1002/mdc3.12231; 
[5]1 Cozac, V.V., Auschra, B., Chaturvedi, M., Gschwandtner, U., Meyer, A., Welge-Lüssen, A., 
Fuhr, P. (2017). Among Early Appearing Non-Motor Signs of Parkinson’s Disease, Alteration of 
Olfaction but Not Electroencephalographic Spectrum Correlates with Motor Function. Frontiers in 
Neurology. DOI: 10.3389/fneur.2017.00545 
[6] Cozac, V.V., Rotaru, L. (2016). [Paradoxical kinesia in Parkinson's disease: theories and 
practical application]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 116(2):109-15. 
Russian. DOI: 10.17116/jnevro201611621109-115; 
[7] Cozac, V.V. (2016). [Modern approaches to treatment of psychosis in Parkinson’s disease. 
Review]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 116(10): 103-109 Russian. DOI: 
10.17116/jnevro2016116101103-109; 
 
B. Abstracts at international meetings 
   [1] Cozac, V.V., Chaturvedi, M., Hatz, F., Meyer, A., Nowak, K., Gschwandtner, U., Fuhr, P. 
(2016) Correlation of the EEG frequency with cognitive performance in Parkinson’s disease – six-
months follow-up. Parkinsonism and Related Disorders. 22;2:e143. DOI: 
10.1016/j.parkreldis.2015.10.598, (presented at the XXIth World Congress on Parkinson’s Disease 
and Related Disorders, Milan, Italy); 
[2] Chaturvedi, M., Bousleiman, H., Cozac, V.V., Gschwandtner, U., Hatz, F., Meyer, A., Schindler, 
C., Zimmermann, R., Fuhr, P. (2016). Quantitative EEG in patients with Parkinson’s Disease (PD) 
with and without Mild Cognitive Impairment (MCI) – Power analysis. Clinical Neurophysilogy. 
127;3:e30-e31. DOI: 10.1016/j.clinph.2015.11.092, (presented at the 15th European Congress on 
Clinical Neurophysiology, Brno, Czech Republic); 
[3] Cozac, V.V., Bogaarts, J.G., Chaturvedi, M., Gschwandtner, U., Hatz, F., Meyer, A., Fuhr, P. 
(2016). Influence of age on quantitative EEG in Parkinson’s disease. Proceedings of the 11th 
International congress on non-motor Dysfunctions in Parkinson's disease and related disorders 
(NMPD-D 2016), Ljubljana, Slovenia; 
[4] Sturzenegger, R., Meyer, A., Chaturvedi, M., Cozac, V.V., Hatz, F.,  Gschwandtner, U., Fuhr, P. 
(2016). Alertness as assessed by clinical testing and alpha reactivity does not correlate with 
executive function decline in Parkinson's disease (PD). Parkinsonism and Related Disorders. 
22;2:e164-5. DOI: 10.1016/j.parkreldis.2015.10.395, (presented at the XXIth World Congress on 
Parkinson’s Disease and Related Disorders, Milan, Italy); 
[5] Chaturvedi, M., Hatz, F., Meyer, A., Cozac, V.V., Gschwandtner, U., Roth, V., Fuhr, P. (2016). 
Can Quantitative EEG (QEEG) differentiate patients with Parkinson's disease (PD) from healthy 
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controls? Parkinsonism and Related Disorders. 22;2:e143. DOI: 
10.1016/j.parkreldis.2015.10.388, (presented at the XXIth World Congress on Parkinson’s Disease 
and Related Disorders, Milan, Italy); 
[6] Cozac, V.V., Chaturvedi, M., Gschwandtner, U., Hatz, F., Meyer, A.., Nowak, K., Sturzenegger, 
R., Fuhr, P. (2016). Predictive performance of EEG theta spectral power over developing dementia 
in Parkinson’s disease. (presented at the 20th International Congress of Parkinson's Disease and 
Movement Disorders, Berlin, Germany); 
[7] Meyer, A., Gschwandtner, U., Cozac, V.V., Hatz, F., Fuhr, P. (2016). How do cognitive profiles 
differ in patients with Parkinson’s disease with cognitive decline in comparison to patients 
remaining cognitively stable? Preliminary results of a 3 years follow-up study. (presented at the 
20th International Congress of Parkinson's Disease and Movement Disorders, Berlin, Germany). 
[8] Cozac, V.V., Bogaarts, J.G., Chaturvedi, M., Meyer, A., Rytz, M., Hatz, F., Gschwandtner, U., 
Fuhr, P. (2017). Olfactory deficits and the EEG-frequency bands in Parkinson’s disease. DOI: 
10.1016/j.clinph.2017.06.201, (presented at the 61st Congress of German Society of Clinical 
Neurophysiology, Leipzig, Germany). 
[9] Chaturvedi, M., Hatz, F., Gschwandtner, U., Meyer, A., Cozac, V.V., Bogaarts, J.G., Roth, V., 
Fuhr, P. (2017). Quantitative EEG and neuropsychological tests to differentiate between 
Parkinson’s disease patients and healthy controls with Random Forest algorithm. DOI: 
10.1016/j.clinph.2017.06.202, (presented at the 61st Congress of German Society of Clinical 
Neurophysiology, Leipzig, Germany). 
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Clinical features of Parkinson’s disease 
As discussed in Chapter 1, PD has motor and non-motor symptoms. The cardinal motor 
symptoms of PD are: rest tremor, muscular rigidity, slowness of movement 
(bradykinesia), and postural and gait instability (Jankovic, 2008). The prevalence of 
certain type of motor symptoms varies from patient to patient; thus, some researchers 
attempted to classify PD according to dominant motor symptoms (Marras and Lang, 
2013). The following motor subtypes were suggested: tremor-dominant (with a relative 
absence of other motor symptoms), non-tremor-dominant (sometimes described as 
akinetic-rigid syndrome), and a mixed subtype.  
Non-motor symptoms of PD comprise a wide range of disorders: neuropsychiatric 
symptoms, sensory symptoms, gastrointestinal symptoms, dopaminergic drug-induced 
behavioural symptoms, sleep disorders, fatigue, autonomic dysfunction, and nonmotor 
fluctuations (Chaudhuri et al., 2011). As in case of motor symptoms, non-motor symptoms 
of PD are heterogenous, and some researchers attempted to classify PD in accordance 
with dominant non-motor symptom. Thus, the following non-motor phenotypes of PD 
were suggested: cortical (cognitive impairment dominant), limbic (comprises subtypes 
with depression, fatigue, pain, and weight-loss), and brainstem (comprises subtypes with 
sleep impairment, and autonomic disorders) (Sauerbier et al., 2016a). 
Non-motor symptoms are frequently present in before the onset of motor symptoms 
in PD, sometimes for years  (Postuma et al., 2012; Sauerbier et al., 2016b). Thus, the clinical 
course of PD is divided in premotor (or prodromal) stage and motor stage (Figure 1; Kalia 
and Lang, 2015).  
Epidemiology of Parkinson’s disease 
The prevalence of PD ranges (per 100'000 inhabitants) from 35.8 to 12'500.0 
depending on the region (Zou et al., 2015; Muangpaisan et al., 2009; von Campenhausen et 
al., 2005). PD has a clear age-dependent prevalence (per 100'000 inhabitants): it is 41 in 
the 40-49 years population group and 1'903 in older than 80 years old (Pringsheim et al., 
2014). The life risk of PD is 2% for males and 1.3% for females (Elbaz et al., 2002), and in 
the 50-59 years old group the prevalence in males is 3.3 times higher than in females 
(Pringsheim et al., 2014). Median age of disease onset is 60 years (Lees et al., 2009), with 
median time from symptom onset to death of just over 12 years (Hely et al., 2005, 2008). 
The commonest cause of death in patients with PD is pneumonia (Beyer et al., 2001; Hely 
et al., 2005). 
 
 
 
Figure 1. Clinical symptoms and time course of Parkinson's disease progression.  
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Diagnosis of Parkinson's disease occurs with the onset of motor symptoms (time 0 years) but can be 
preceded by a premotor or prodromal phase of 20 years or more. This prodromal phase is characterised 
by specific non-motor symptoms. Additional non-motor features develop following diagnosis and with 
disease progression, causing clinically significant disability. Axial motor symptoms, such as postural 
instability with frequent falls and freezing of gait, tend to occur in advanced disease. Long-term 
complications of dopaminergic therapy, including fluctuations, dyskinesia, and psychosis, also contribute 
to disability. EDS=excessive daytime sleepiness. MCI=mild cognitive impairment. RBD=REM sleep 
behaviour disorder. 
With permission from Elsevier (source: Kalia and Lang, 2015) 
 
Aetiology of Parkinson’s disease 
The precise cause of PD, despite decades of intensive study, is still the subject of 
research (Przedborski, 2017). Some proportion of cases of PD is related to genetic factors 
(Redenšek et al., 2017), another proportion – to environmental and lifestyle factors, e.g. 
exposure to toxicants, depression, head injury (Goldman, 2014; Lill and Klein, 2017). In 
most cases no specific cause is identified and the disease is referred to as idiopathic PD2. 
However, it is likely that PD is caused by a combination of genetic and environmental 
causes (multifactorial origin).   
Genetic factors of Parkinson’s disease 
Genetic factors have been estimated to explain about 5% of the genetic variance of PD, 
while the common heritable component of PD estimated with missing heritability analysis 
explained 27% of PD (Keller et al., 2012). Even more, some leading researchers consider 
that genetics is a central component to every case of PD using an illustrative hyperbole “if 
you’re not working with genetics, you’re not working on Parkinson’s disease” (Singleton et 
al., 2017). In the genetic nomenclature of PD, chromosomal regions which contain genes 
associated with PD – these regions are also called loci (sing. locus) – were termed “PARK” 
and numbered in chronological order of their discovery (e.g. PARK1, PARK2 etc.). A large 
meta-analysis based on genome-wide association studies (GWAS) has identified 24 loci 
associated with risk for PD (Nalls et al., 2014). With the increase of possible genetic 
associations and combinations due to the research advance, not all of those loci are 
termed PARK. Mutations in some of these genes cause PD by the nature of the things: they 
                                                          
2 Greek: idios – one's own + pathos  – disease; literally “a disease of its own kind”. 
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are called causal genes, and cause monogenic forms of PD. Currently, mutations in five loci 
are known as confirmed monogenetic factors of PD and are listed in the Parkinson disease 
Mutation Database (PDmutDB)  (Table 1) (Parkinson Disease Mutation Database 
(PDmutDB, available online3); Cruts et al., 2012).  
In case of some other genes, the association with PD is less conclusive and these genes 
are the subject to ongoing research (Table 2). Usually such genes are referred to as risk 
factors or susceptibility loci of PD. 
In addition, the concept of epigenetics gained attention in recent years in the research 
of PD. The term „epigenetics“4 refers to stable and heritable changes in gene expression 
(phenotype) without any mutation of this gene. Such changes occur through different 
mechanisms: chemical (covalent) modifications of DNA (e.g. methylation, acetylation), 
formation of non-coding RNA, and histone modifications (Ciceri et al., 2017). 
Table 1. Confirmed monogenetic associations of PD 
HGNC - Human Genome Organisation Gene Nomenclature Committee; ADom - autosomal-dominant; ARec - 
autosomal-recessive 
Gene HGNC  No of 
identified 
mutations 
Type of 
Mendelian 
inheritance5 
Reference6 
Alpha-
synuclein 
PARK1/ 
PARK47 
27 ADom Polymeropoulos et al., 1997  
Parkin PARK2 214 ARec Hattori et al., 1998  
PINK1 PARK6 138 ARec Groen et al., 2004 
DJ-1 PARK7 28 ARec Abou-Sleiman et al., 2003 
LRRK2 PARK8 128 ADom Zimprich et al., 2004 
 
Table 2. Unequivocal genetic associations or risk factors of PD 
HGNC - Human Genome Organisation Gene Nomenclature Committee 
Gene HGNC  Reference 
Unidentified, possible SPR PARK3 Gasser et al., 1998; Sharma et al., 2006  
UCHL1 PARK5 Leroy et al., 1998 
ATP13A2 PARK9 Schneider et al., 2010 
Unidentified, possible 
TCEANC2, TMEM59, miR-4781, 
LDLRAD1 
PARK10 Hicks et al., 2002; Beecham et al., 2015 
GIGYF2 (?)8 PARK11 Pankratz et al., 2002 
Unidentified PARK12 Pankratz et al., 2003 
HTRA2 PARK13 Strauss et al., 2005 
                                                          
3 http://www.molgen.vib-ua.be/PDMutDB/default.cfm?MT=1&ML=0&Page=PDmutDB 
4 Greek: epi – outside + genetics; literally “in addition to genetics”. 
5 It should be stressed, however, that in clinical practice the pedigrees rarely follow a strict Mendelian pattern due to such 
factors as reduced penetrance, variable expressivity and phenocopy phenomena (Klein and Westenberger, 2012) 
6 Only the first publication in chronological order of appereance is shown, for a full list list of related references please access 
PDmutDB online database; 
7 Locus PARK4 was designated as a novel chromosomal region in 1999, but later was found to be identical with PARK1 
(Singleton et al., 2003). 
8 Initial reports on associations of GIGYF2 with PD were contested (Di Fonzo et al., 2009b);  
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PLA2G6 PARK14 Paisán-Ruiz et al., 2009; Lu et al., 2012; Miki et al., 
2017 
FBX07 PARK15 Di Fonzo et al., 2009a; Lohmann et al., 2015 
Unidentified, possible SLC41A1 PARK16 Wang et al., 2017 
VPS35 PARK17 Tsika et al., 2014; Khurana et al., 2017 
EIF4G1 PARK18 Chartier-Harlin et al., 2011 
GBA GBA Sidransky and Lopez, 2012 
MAPT MAPT Valenca et al., 2016 
COMT COMT Jiménez-Jiménez et al., 2014 
APOE APOE Wilhelmus et al., 2011 
Environmental factors of Parkinson’s disease 
A number of environmental factors are associated with the development of PD; they 
include: exposure to toxins (metals, pesticides, solvents), rural living and agricultural 
occupation (which are presumed indirect measures of exposure to toxins), head injury, 
stress and depression (Kwakye et al., 2016; de Lau and Breteler, 2006; Di Monte et al., 
2002).  
Table 3. Environmental factors of PD 
Factor Reference 
Exposure to pesticides (e.g. rotenone, dieldrin) Tanner et al., 2011; Kanthasamy et al., 2008 
Exposure to heavy metals (manganese, iron, 
copper) 
Kwakye et al., 2015; Willis et al., 2010 
Exposure to solvents (e.g. trichloroethylene) Goldman et al., 2012 
Rural living and farming activity Kab et al., 2017; Moisan et al., 2011  
Neurotoxin MPPT Langston et al., 1999 
Methamphetamine Curtin et al., 2015 
Traumatic head injury Ha et al., 2016 
Stress and depression Hemmerle et al., 2012 
Lower uric acid serum level Wen et al., 2017 
Lower vitamin D serum level Rimmelzwaan et al., 2016 
 
Potential protective factors  
Certain environmental factors are referred to as neuroprotective agents, because data 
from the epidemiological studies showed decreased incidence of PD in the presence of 
such factors. Neuroprotective factors include: tobacco consumption (Li et al., 2015), and 
coffee consumption (Costa et al., 2010). Less confident association was found between 
decreased risk of PD and alcohol consumption (Bettiol et al., 2015) and nonsteroidal anti-
inflammatory drug ibuprofen (Ascherio and Schwarzschild, 2016). 
 
In conclusion, the exact aetiology of PD in the majority of individuals remains unknown, 
but both genetic and environmental factors may contribute (Fig. 2). Additionally, there is 
growing evidence that epigenetics may provide a comprehensive answer to the problem 
of aetiology of PD. Some researchers suggested a unifying understanding of how different 
causes of PD relate one to one another (McNaught et al., 2001; Wong and Krainc, 2017), 
hypothesising that dysfunctions of protein degradation might be an important factor in 
the degenerative processes that occur in the various aetiological forms of PD. 
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Figure 2. Possible interplay between aetiological factors of PD 
 
The presence of risk genes and male sex, brain injuries, ageing and exposure to toxins increase the risk of 
having PD, while tobacco and coffee consumtion was found to be associated with a lower risk of PD. 
 
 Pathophysiology of Parkinson’s disease 
The pathological diagnosis of PD is characterized by two cardinal morphopathological 
findings: death of dopaminergic neurons, located in basal ganglia (namely in pars 
compacta of substantia nigra), and abnormal cytoplasmatic aggregates of proteins called 
Lewy bodies, located in the the surviving neurons. A major protein of Lewy bodies is an 
abnormally modified form of alpha–synuclein (SNCA), which is normally located in 
presinaptical regions of neurons. The exact mechanism of this neuronal death is not 
resolved and several theories are proposed (Tansey and Goldberg, 2010). Some of these 
include:  
a) disfunction of alpha–synuclein metabolism, which leads to its fibrillization and 
aggregation and staged dissemination in the brain (Braak et al., 2003); 
b) disruption of autophagy mechanism (Ghavami et al., 2014); 
c) disruption of mitochondrial function (Chen and Chan, 2009); 
d) microglial inflammation (Glass et al., 2010); 
e) neurovascular disfunction (Zlokovic, 2011); 
Importantly, there is a clear evidence, that the pathophysiology of PD is not limited to 
dopaminergic neurons of substantia nigra, but implicates a distributed brain network: 
putamen, striatum, thalamus, brainstem, and cortex (Galvan and Wichmann, 2008). 
Cognitive decline in Parkinson’s disease 
As discussed above, cognitive impairment is an important non-motor symptom in PD 
and has a considerable impact on functioning, quality of life, caregiver burden, and health-
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related costs (Svenningson et al., 2012). Cognitive deficits are present throughout the 
whole course of PD, from initial to advanced stages (Pagonabarraga and Kulisevsky, 2012). 
The profile and incidence of cognitive decline vary a lot among PD patients (Aarsland et 
al., 2017). The spectrum of PD related cognitive decline includes three  syndromes of 
various severity (from mild to severe): subjective cognitive decline (SCD), mild cognitive 
impairment (PD-MCI), and PD-D. Subjective cognitive decline gained research interest 
during the recent years; in this syndrome, no clinical evidence (normal cognitive test 
performance) of cognitive deficits is found, but such deficits are noted by patients 
themselves or family members and caregivers. Currently, no consensus criteria for SCD 
exist, but many researchers report SCD in PD patients as a harbinger of future cognitive 
deterioration (Erro et al., 2014). In PD-MCI, cognitive deficits are identified by cognitive 
test performance, but these deficits do not impair daily life of the patient (i.e. socail and 
professional activity), independently of the impairment caused by motor or other than 
cognitive features of PD (Litvan et al., 2012). Finally, cognitive deficits in PD-D are severe 
enough to impact daily life and independence of patients (Emre et al., 2007).  
However, the aforementioned cognitive syndromes are consecutive, and nearly all 
patients will be affected over time, thus the separation between the stages of cognitive 
deterioration in PD – normal cognition, SCD, PD-MCI and PD-D – is not strict and 
significantly varies depending on the applied criteria and cognitive measurement 
procedures utilized (Aarsland et al., 2017). 
Dementia (severe cognitive disorder) in Parkinson’s disease 
Several studies have shown that the point prevalence of dementia in patients with PD 
is about 30%, and that the incidence rate of dementia in PD is 4 – 6 times higher than in 
healthy subjects (Aarsland et al., 2005a; Riedel et al., 2008; Kim et al., 2009). The 
cumulative prevalence of dementia in patients with PD ranges from 5.4% to 19.2% after 
five years9 (after diagnosis of PD) (Santangelo et al., 2015; Pedersen et al., 2013), to 46% 
after ten years (Williams-Gray et al., 2013), and 83% after surviving more than twenty 
years (Hely et al., 2008). PD-D is associated with a twofold increase in mortality (Levy et 
al., 2002), increased caregiver strain (Aarsland et al., 2007a) and increased healthcare 
costs (Vossius et al., 2011). 
 Diagnostics of dementia in Parkinson’s disease 
Before 2007, no specific diagnostic criteria for PD-D existed. A diagnosis of PD-D was 
set up on the grounds of generic neuropsychiatric criteria, i.e. according to the Diagnostic 
and Statistical Manual of Mental Disorders fourth edition (DSM-IV; American Psychiatric 
Association, 1994). The specifically aimed diagnostic criteria for PD-D were defined in the 
guidelines of the International Parkinson and Movement Disorders Society (MDS; Emre et 
al., 2007). The core defining feature of PD-D in these guidelines is the emergence of 
dementia in the setting of established PD (Panel 1). Dementia is defined as a syndrome of 
insidious onset and progressive decline of cognition and functional capacity from a 
premorbid level, that is not attributable to motor or autonomic symptoms. The guidelines 
                                                          
9 Discrepancies in results between studies are likely to be explained by differences in case selection, use of different criteria 
for PD-MCI and PD-D, and loss to follow‑up (Aarsland et al., 2017). 
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with neuropsychological assessment methods to be carried out with patients with 
suspection to PD-D were published by the same workgroup (Dubois et al., 2007). 
Panel 1. MDS diagnostics guidelines for PD-D (from Emre et al., 2007) 
I. Core features 
1. Diagnosis of PD according to Queen Square Brain Bank criteria (Hughes et al., 1992); 
2. A dementia syndrome with insidious onset and slow progression, developing within the 
context of established PD and diagnosed by history, clinical, and mental examination, defined as: 
- Impairment in more than one cognitive domain; 
- Representing a decline from premorbid level; 
- Deficits severe enough to impair daily life (social, occupational, or personal care), 
independent of the impairment ascribable to motor or autonomic symptoms. 
II. Associated clinical features 
1. Cognitive features: 
- Attention: impaired. Impairment in spontaneous and focused attention, poor 
performance in attentional tasks; performance may fluctuate during the day and 
from day to day; 
- Executive functions: Impaired. Impairment in tasks requiring initiation, planning, 
concept formation, rule finding, set shifting or set maintenance; impaired mental 
speed (bradyphrenia); 
- Visuo-spatial functions: Impaired. Impairment in tasks requiring visual-spatial 
orientation, perception, or construction; 
- Memory: Impaired. Impairment in free recall of recent events or in tasks requiring 
learning new material, memory usually improves with cueing, recognition is usually 
better than free recall; 
- Language: Core functions largely preserved. Word finding difficulties and impaired 
comprehension of complex sentences may be present; 
2. Behavioral features: 
- Apathy: decreased spontaneity; loss of motivation, interest, and effortful behavior; 
- Changes in personality and mood including depressive features and anxiety; 
- Hallucinations: mostly visual, usually complex, formed visions of people, animals or 
objects; 
- Delusions: usually paranoid, such as infidelity, or phantom boarder (unwelcome 
guests living in the home) delusions; 
- Excessive daytime sleepiness. 
III. Features which do not exclude PD-D, but make the diagnosis uncertain 
1. Co-existence of any other abnormality which may by itself cause cognitive impairment, but 
judged not to be the cause of dementia, e.g. presence of relevant vascular disease in imaging; 
2. Time interval between the development of motor and cognitive symptoms not known. 
IV. Features suggesting other conditions or diseases as cause of mental impairment, which, 
when present make it impossible to reliably diagnose PD-D 
1. Cognitive and behavioral symptoms appearing solely in the context of other conditions such 
as: 
- Acute confusion due to 
a) Systemic diseases or abnormalities 
b) Drug intoxication 
- Major Depression according to DSM IV 
2. Features compatible with “Probable Vascular dementia” criteria according to NINDS-
AIREN10 (Erkinjuntti, 1994) (dementia in the context of cerebrovascular disease as indicated by 
focal signs in neurological exam such as hemiparesis, sensory deficits, and evidence of relevant 
                                                          
10 NINDS-AIREN - National Institute of Neurological Disorders and Stroke and Association Internationale pour la Recherché 
et l'Enseignement en Neurosciences 
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cerebrovascular disease by brain imaging AND a relationship between the two as indicated by the 
presence of one or more of the following: onset of dementia within 3 months after a recognized 
stroke, abrupt deterioration in cognitive functions, and fluctuating, stepwise progression of 
cognitive deficits) 
 
 
Distinction between dementia in Parkinson’s disease and dementia with Lewy 
bodies 
 Clinical, neuropsychological and neuropathological features of PD-D overlap with 
those of dementia with Lewy bodies (DLB). Currently, DLB is recognized as distinct 
nosological entity, a type of dementia which rapidly progresses over time. The 
distinguishing clinical and pathological features of DLB are presence of Lewy bodies in 
neurons of the cerebral cortex (unlike the «classic» Lewy bodies of PD, which are found 
in basal ganglia) and very rapid progression to cognitive decline after the onset of 
parkinsonian-type motor impairment. Additionally, dementia in case of DLB is 
characterized with fluctuating cognition with pronounced variation in attention and 
alertness, recurrent visual hallucinations, severe neuroleptic sensitivity, and association 
with REM sleep behavior disorder (Mrak and Griffin, 2007). In the criteria of DLB 
consortium the distinction between PD-D and DLB is made solely on the temporal 
sequence of cognitive symptoms to motor onset (McKeith et al., 2005). Those patients who 
develop cognitive impairment within one year after motor onset (or prior to motor 
symptoms) are classified as DLB, and those patients, who develop cognitive impairment 
after longer than one year after motor onset, are classified as PD-D («one year rule»). 
However, in the revised MDS criteria for PD (2015), a DLB subtype of PD was introduced 
to define cases with rapid progression to dementia regardless the timing of cognitive 
impairment to motor impairment (Postuma et al., 2015). Thus, the distinction between 
PD-D and DLB is blurred and requires further exploration. The overlap in symptoms and 
other evidence suggest that DLB and PD-D (and PD per se) may be linked to the same 
underlying abnormalities of alpha–synuclein. A generic term “Lewy body disease” is used 
to encompass both DLB and PD-D (Brenowitz et al., 2017). 
Pathophysiology of dementia in Parkinson’s disease 
The pathophysiology of PD-D is not yet fully understood. There is a number of 
theories explaining cognitive deterioration within PD. In most of such theories, the 
emergence of cognitive deficits is related to neurodegenerative process. Potential factors 
contributing to PD-D encounter Lewy bodies, α-synuclein interactions, beta-amyloid 
aggregates, and neurotransmitter dysfunction.  
Some researchers postulated that the accumulation of Lewy bodies in the limbic 
system and cortex is the main substrate of cognitive decline in PD (Apaydin et al., 2002; 
Aarsland et al., 2005b). According to Braak hypothesis (Braak et al., 2004, 2005), PD-D 
emerges when Lewy body pathology spreads to the limbic and cortical regions (this 
corresponds to Braak stages 5 and 6, figure 3). 
Figure 3. The Braak staging system of Parkinson disease 
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The Braak staging system of Parkinson disease, showing the initiation sites in the olfactory bulb and the 
medulla oblongata, through to the later infiltration of Lewy pathology into cortical regions. 
α-Synuclein-related pathology is possibly initiated in the periphery via input from the olfactory epithelium 
or vagal inputs from the stomach, perhaps involving xenobiotic factors. The red shading represents the 
pattern of pathology. 
With permission from John Wiley and Sons (source: Halliday et al., 2011). 
 
 Kramer and Schulz-Schaeffer (2007)  demonstrated that PD-D is related to the 
damage of synapses caused by pre-synaptic α-synuclein. Other researchers pointed out to 
the importance of beta-amyloid aggregation (Halliday and McCann, 2010; Compta et al., 
2011). And some other publications highlighted the influence of neurotransmitter 
systems dysfunction in the development of PD-D, i.e. cholinergic (Calabresi et al., 2006; 
Jellinger, 2006; Bohnen and Albin, 2011a), noradrenergic and serotonergic (Cirrito et al., 
2011; Kotagal et al., 2012). 
In conclusion, the pathophysiological process behind PD-D is heterogeneous and 
multifactorial as PD itself. Better understanding the mechanism of cognitive deterioration 
in PD is warranted and will significantly contribute to prediction and treatment in the 
future. 
Deep brain stimulation and dementia in Parkinson’s disease 
As discussed in Chapter 1, DBS is a surgical implantation of an electrical pulse 
generator with electrodes projected to specific targets in the brain. DBS has provided 
satisfactory therapeutic benefits for some neurological and psychatric disorders resistant 
to conservative treatment: i.e. PD, essential tremor, dystonia, and depression (Kringelbach 
et al., 2007). In recent years, it has been largely acknowledged that DBS can alleviate 
motor symptoms of PD, though the exact mechanisms of therapeutic effects of DBS are 
still not fully resolved (Garcia et al., 2013).  
Two surgical targets are considered the most common procedures for DBS in PD: 
subthalamic nucleus and globus pallidus internus (GPi). Proponents of GPi-DBS, mostly in 
the North America, consider that targeting GPi causes less behavioural side-effects, being 
equally effective (Hariz, 2017; Williams et al., 2014). Cognitive impairment in PD is a 
limiting factor for the selection of candidates for DBS, also evidence has been 
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accumulating regarding changes in cognitive performance after DBS itself (Massano and 
Garett, 2012). 
In a comparative meta-analysis of STN-DBS vs. GPi-DBS in terms of cognitive and 
psychiatric effects it was found that STN-DBS was associated with a decline in global 
cognition, attention, working memory, verbal fluency, and memory ; however, there were 
no differences in terms of quality of life and psychiatric effects (Wang et al., 2016). 
In a meta-analysis of 10 controlled studies of DBS to the subthalamic nuclei, an 
association with postoperative decline in global cognition, memory, phonemic fluency, 
semantic fluency, and executive function was found (Xie et al., 2016).  
Biomarkers of dementia in Parkinson’s disease 
The term “biomarker”11 refers to a broad category of medical signs which can be 
measured accurately and reproducibly (Strimbu and Tavel, 2010). A more specific 
definition refers to biomarker as “any substance, structure, or process that can be measured 
in the body or its products and influence or predict the incidence of outcome or disease” 
(WHO, 2001). Amur et al. (2015) suggested to classify biomarkers in the following four 
types: 1) diagnostic - these distinguish between patients with a pathological condition 
and healthy patients; 2) prognostic – these provide information on the possible course 
of untreated disease, in other words, prognostic biomarkers inform about the severity of 
the disease in the absence of treatment; 3) predictive – these  provide information on the 
possible course of a treated disease, in other words predictive biomarkers inform about 
the  potential for a patient to respond (favorably or not) to a treatment; 4) response - 
these are dynamic assessments in the course of a treatment, which identify a presence of 
a biological response to a therapeutic intervention. With regard to the focus of the present 
dissertation, we are searching for prognostic biomarkers, i.e. parameters which provide 
information on the likely course of cognitive decline in PD. There are many biomarkers 
that have been proposed as possible candidates for the development of PD-D; these cover 
various clinical and technological modalities (Tables 4.1-3). Evidence has shown that 
certain clinical factors are associated with higher risk of cognitive decline in PD (Table 
4.1).  
Table 4.1. Potential clinical biomarkers of PD-D 
Factor Marker Reference12 
Age advance of age, particularly age 
over 70 
Aarlsland et al., 2007b 
Sex males Levy et al., 2000 
Education low educational level Levy et al., 2000 
Neuropsychological 
tasks performance 
poor performance in tests that 
involve more posterior cortical 
function (i.e. verbal fluency) 
Williams-Gray et al., 2007 
 
Visual hallucinations  presence Galvin et al., 2006 
Rapid-eye-movement sleep 
behavior disorder 
presence Boot et al., 2012 
Olfactory dysfunction decrease of olfaction Baba et al., 2012 
                                                          
11 Portmanteau of “biological marker” 
12 Full list of references for each factor is not provided 
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Blood pressure high baseline blood pressure 
and orthostatic blood pressure 
drop 
Anang et al., 2014 
Color visions  abnormal color visions Anang et al., 2014 
Gait baseline gait dysfunction Anang et al., 2014 
 
Neuroimaging methods used to predict PD-D have included both structural and 
functional techniques (Table 4.2). Structural methods are based on the assessment of 
cortical atrophy in temporal, parietal and occipital cortices, hippocampus and amygdala, 
and on the assessment of white matter changes. Functional methods are focused on the 
assessment of regional hypoperfusion, glucose metabolism and neurotransmitter activity. 
Table 4.2. Potential neuroimaging biomarkers of PD-D 
Modality Method  Marker Reference13 
Magnetic resonance 
imaging 
voxel-based 
morphometry 
atrophy in temporal, 
parietal and occipital 
cortices 
Weintraub et al., 2011; 
Melzer et al., 2012 
region of interest reduced hippocampal and 
amygdala volumes 
Compta et al., 2012; 
Bouchard et al., 2008 
cortical-thickness 
analysis 
cortical thickness in the 
anterior temporal, 
dorsolateral prefrontal, 
posterior 
cingulate, temporal 
fusiform and 
occipitotemporal cortex 
Zarei et al., 2013 
 
white matter 
lesions 
white matter 
hyperintensities 
Lee et al., 2010 
diffusion tensor 
imaging 
bilateral parietal white 
matter changes 
Hattori et al., 2012 
arterial spin 
labelling 
regional hypoperfusion in 
posterior cortex. 
Le Heron et al., 2014 
Positron emission 
tomography 
glucose metabolism 
with radiotracer 
18F-deoxyglucose 
(FDG) 
 
decreased perfusion in 
occipital and posterior 
cingulate cortices 
Bohnen et al., 2011b 
 
acetylcholinesterase 
activity with 
radiotracer 
[11C]PMP14 
decreased 
acetylcholinesterase 
activity in frontal, parietal 
and temporal cortex 
Bohnen et al., 2003 
beta-amyloid load 
with radiotracer 
Pittsburgh 
compound B 
higher tracer retention 
correlated with cognitive 
decline 
Gomperts et al., 2013 
                                                          
13 Full list of references for each method is not provided 
14 1-[11C]methylpiperidin-4-yl propionate 
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tau protein load 
with radiotracer 
[18F]T807 
higher tracer retention 
in the inferior temporal 
gyrus and precuneus 
Gomperts et al., 2016 
Single-photon 
emission computer 
tomography 
perfusion hypoperfusion in bilateral 
posterior parietal and 
occipital areas 
Nobili et al., 2009 
dopamine 
transporter density 
with radiotracer 
Ioflupane (123I) 
(DaTSCAN) 
decreased DAT in caudate 
nucleus  
Colloby et al., 2012 
 
Analytes of cerebrospinal fluid (CSF) showed some promising results as candidates for 
markers of PD-D (Table 4.3). According to a number of recent reports, patients with PD-
D have lower levels of CSF amyloid beta 1-42. Investigation of concentration of α‑
synuclein and tau proteins (total and phosphorilated) in CSF showed less consistent 
results. Finally, there is some evidence that plasmatic decrease of epidermal growth factor 
and increase of tumor necrosis factor are associated with worse cognition in PD. 
Table 4.3. Potential biological fluid markers of PD-D 
Fluid Substance Marker Reference15 
Cerebrospinal fluid Amyloid Beta 1-42 decreased concentration Compta et al., 2013 
Tau  mixed results16 Compta et al., 2009; 
Siderowf et al., 2010 
α‑synuclein mixed results17 Stewart et al., 2014 
Sako et al., 2014 
Plasma epidermal growth factor decreased concentration Chen-Plotkin et al., 
2011 
tumor necrosis factor increased concentration Menza et al., 2010 
 
Genetic and neurophysiological markers of PD-D will be discussed in Chapter 3. 
Management of cognitive decline in Parkinson’s disease 
There is evidence of the efficacy and safety of cholinesterase inhibitors to treat severe 
cognitve decline in PD (Wang et al., 2015). Rivastigmine and donepezil were reported to 
have satisfactory effects in two large randomised controlled trials: respectively EXPRESS 
(Emre et al., 2004) and EDON (Dubois et al., 2012). Less supportive data were reported for 
an NMDA-receptor antagonist memantine (Aarsland et al., 2009). Some pharmaceutical 
agents are candidate-drugs for trials in PD-D, basing on theoretical and preliminary 
empirical evidence. Some of these are: selective monoamine oxidase B inhibitor rasagiline 
                                                          
15 Full list of references for each marker is not provided; 
16 Some studies (Compta et al. 2009) reported an association between increased levels and cognitive impairment, but others 
reported no associations (Siderowf et al., 2010); 
17 Meta-analysis by Sako et al., 2014, showed decreased level of α‑synuclein in PD-D, while Stewart et al., 2014, showed 
better preservation of cognitive function over time in patients with lower level of α‑synuclein  
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(Weintraub et al., 2016) and selective noradrenaline reuptake inhibitor atomoxetine 
(Weintraub et al., 2010). 
Some potential disease-modifying strategies (slowing the onset of PD-D) are an urgent 
unmet need. These include immunotherapies targeting beta-amyloid, tau-proteins and 
alpha‑synuclein, drugs addressing mitochondrial dysfunction, anti-inflammatory agents, 
GBA-active agents, stimulation of neurogenesis, and neurotrophic factors (Aarsland et al., 
2017). 
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Chapter 3. Genetic and EEG markers of dementia in Parkinson’s 
disease 
Genetic markers  
Genetic markers of cognitive decline in PD came in focus of the research since the 
discovery of the first genetic causes of PD per se. A number of genes associated with 
cognitive impairment in PD have been identified, however the studies yielded sometimes 
conflicting results (Aarsland et al., 2017; Collins and Williams-Gray, 2016) (Table 5).  
Naturally, causal genes of PD were investigated with relation to parkinsonian non-
motor symptoms, like cognitive and psychiatric impairment. Mutation in Leucine-rich 
repeat kinase 2 (LRRK2) gene, locus PARK8, is the most studied mutation (Aarsland et al., 
2017). However, it showed no influence on cognition in the most of the studies, instead it 
even had some protective effect (Srivatsal et al., 2015; Ben Sassi et al., 2012; Alcalay et al., 
2010). Mutations in alpha-synuclein (SNCA) gene, locus PARK1/4,  also showed some 
association with dementia in PD (Somme et al., 2011; Farrer et al., 2004), however 
contested in one study (Mata et al., 2014).  
Among the risk factor genes of PD, the following genes were mostly investigated: 
glucocerebrosidase (GBA), apolipoprotein E (APOE), microtubule-associated protein Tau 
(MAPT) and catechol-O-methyltransferase (COMT).  
Glucocerebrosidase gene 
GBA is an lysosomal enzyme of glicolipid metabolism, which is responsible for the 
hydrolysis of glucocerebroside (Brady et al., 1965).  GBA showed the most significant 
correlation with a phenotype with severe cognitive decline (Brockmann et al., 2014; 
Winder-Rhodes et al., 2013; Setó-Salvia et al., 2012). The mechanism behind the relation of 
GBA mutations to PD-D is still not entirely clear. One theory proposes that impaired GBA 
(due to the mutation of the gene) activity of GBA enzyme and accumulation of 
glucocerebroside in the lysosomes acts as a backbone for alpha-synuclein aggregation in 
the neurons (Mazzuli et al., 2011). 
Apolipoprotein E gene 
APOE is a plasmatic protein-carrier of  cholesterol, essential in lipidic metabolism in 
the brain (Puglielli et al., 2003). APOE gene is polymorphic and has three major alleles: ɛ2, 
ɛ3, and ɛ4. Whilst ɛ4-allele of APOE has been established as a risk factor for the 
development of Alzheimer’s disease (AD) (Farrer et al., 1997), studies showed an over-
representation of ɛ4 among cases with PD dementia (Morley et al., 2012; Williams-Gray et 
al., 2009a), showing a potential genetic overlap between PD-D and AD. However, these 
results were not confirmed in another study (Kurz et al., 2009). It is thought that the 
relation of ɛ4-allele with PD-D may be mediated (at least in part) through altered amyloid 
metabolism (Gallardo et al., 2008). 
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Microtubule-Associated Protein Tau gene 
MAPT is a protein involved in the assembly and stabilization of axonal microtubules. 
The MAPT gene has two haplogroups, H1 and H2, in which the gene fragment appears in 
inverted orientations. Thus, a genotype may contain the following MAPT haplotype 
variants: H1/H1, H2/H2, and H1/H2 (Stefansson et al., 2005). A strong evidence on 
association between the MAPT gene H1/H1-haplotype and cognitive decline in PD was 
shown in observational studies (Williams-Gray et al., 2009b, 2013; Setó-Salvia et al., 2011), 
in another studies this association was not confirmed (Mata et al., 2014; Morley et al., 
2012). The mechanism by which the H1 variant might cause lead to worsening of 
cognition in PD is unknown, but increased expression levels of total tau has been reported 
in PD (Collins and Williams-Gray, 2016). 
Catechol-O-methyl Transferase gene 
COMT is an enzyme which degrades catecholamine neurotransmitters (i.e. dopamine, 
epinephrine, and norepinephrine). COMT gene contains a functional polymorphism, 
which results in valine to methionine mutation at position 158 (Val158Met) (Schacht, 
2016). An association between alterations of executive and attention cognitive domains 
in PD and val-158-met-allele of COMT gene was demonstrated in some studies (Williams-
Gray et al., 2009b; Foltynie et al., 2004). However, this genetic variant does not appear to 
be associated with dementia risk (Williams-Gray et al., 2009b; Collins and Williams-Gray, 
2016). 
Table 5. Genetic associations of cognitive decline in PD 
Gene  Role in the pathology of 
PD  
Features of PD phenotype 
SNCA  causal gene early onset rapidly progressive dementia 
MAPT H1/H2 
hapotype 
risk factor higher dementia risk of dementia in carriers  
GBA  risk factor rapid progression to dementia 
COMT val-158-met 
polymorphism 
no proven relation associated with altered executive and attention 
tasks 
APOE ɛ4 allele no proven relation higher dementia risk of dementia in carriers 
 
Quantitative EEG markers  
Quantitative EEG is a mathematical processing of EEG data to extract relevant 
information for subsequent analysis or comparison with other kind of data (Nuwer, 1997; 
Thakor and Tong 2004). In contrast to conventional EEG, where electrical activity of the 
brain cells is visually analyzed, qEEG provides derivative parameters, which are 
generated from EEG “raw” data using computational methods. Quantitative EEG includes 
several procedural steps (Fig. 4). The first step consists of EEG signal acquisition itself - 
performed with the use of various EEG machines and electrode systems. Alternatively, 
magnetoencephalography (MEG) may be used. MEG is the recording of the magnetic 
fields, generated by the ionic currents at the brain cellular level; thus, both EEG and MEG 
are methodologically similar and relevant in neuroscience (Lopes da Silva, 2013). The 
second step includes preprocessing - eliminating the following artifacts: muscle 
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movements, sleepiness, eye blinks, heart beat and other types of EEG “noise”. 
Preprocessing is performed by selecting “clean” EEG segments for analysis. The last stage 
is mathematical processing of the “clean” (artifact-free) EEG signal to extract a parameter, 
which denotes best the process of interest (e.g. cognitive decline). Various mathematical 
approaches are used for the processing; they are generally classified in linear and non-
linear techniques. Linear methods are based on the concept that electric activity of the 
brain is a stationary process (Al-Qazzaz et al., 2014). Non-linear methods are based on the 
concept that EEG activity is a dynamic and irregular phenomenon (Kantz and Schreiber, 
2004). Each of these methods has its advantages and disadvantages (Netoff et al, 2006; 
Blinowska 2011). 
Fig. 4. Outlines of the qEEG process.  
 
A. Main steps of the processing; B. Spectral and functional connectivity measures 
 
Spectral analysis 
Spectral analysis is a linear technique of EEG processing. It is a process by which a 
complex EEG signal is decomposed into its component frequencies, and the amplitude of 
oscillations at each frequency bin is calculated. Since oscillations around zero (like an EEG 
trace) would add up to 0, amplitudes are represented by their squares, called power. The 
totality of powers at each frequency band is called power spectrum and could be 
represented as a graph (Fig. 5).  
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Figure 5. Power spectra. 
 
Spectra of a healthy person (A), a patient with PD-MCI (B), and a patient with PD-D (C); band power: 8-13 Hz. 
Images computed from the own EEG data using „TAPEEG“ toolbox. 
 
Thus, a power spectrum reflects “the amount of activity” in frequency bands. The 
frequency bands are the same as used in conventional EEG, generally consisting of delta 
(0.1-3.5 Hz), theta (4-7.5 Hz), alpha (8-13 Hz), beta (14-30 Hz), gamma (>30 Hz) 
(Niedermeyer and Lopes da Silva, 2005). However, different researchers may select slightly 
different frequency intervals for their analyses. Additionally, the bands could be divided 
into sub-bands, e.g. alpha1 (8-10 Hz) and alpha2 (10-13 Hz), for the purpose of a thorough 
analysis. Spectral power can be absolute or relative. Absolute power in a given frequency 
band, e.g. in the alpha band,  corresponds to the integral of all power values as measured, 
while relative power is the power in a given frequency band divided by the sum of all 
power measurements of all frequencies. Additionally, power could be global and regional. 
Global power reflects the average power over the whole cortex, while regional power 
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characterizes the power in certain cortex regions. Mainly, five regions in each hemisphere 
are analyzed: frontal, temporal, parietal, occipital and central, giving a total of 10 regions. 
Additionally, some average parameters of EEG frequency can be obtained in spectral 
analysis (Otto 2008). Mean frequency (also referred to as mean “power frequency” or 
“spectral centre of gravity”) is calculated as the sum of the product of the power spectrum 
and the frequency divided by the total sum of the power spectrum. Median frequency is 
the 50% quantile of the power spectrum, in other words, it is the frequency at which the 
power spectrum is divided into two regions with equal amplitude. Finally, peak frequency 
is the frequency which corresponds to the maximum of the power spectrum.  
Functional connectivity analysis 
 The other type of information obtained by qEEG (apart from spectral analysis) is 
functional brain connectivity. Functional connectivity in the context of neuronal activity 
may be briefly defined as a coordinated interplay between specialized brain regions 
(Fingelkurts et al., 2005). Cognitive functions (e.g. attention, memory) arise from neuronal 
activity, which is distributed over the brain anatomically and temporally, forming 
complex networks (Palva and Palva, 2012). These networks function on the basis of 
anatomical connections (white matter tracts connecting brain regions), functional 
connections (temporal correlations between brain regions, even anatomically 
unconnected), and effective connections (causal influences between networks) (Rubinov 
and Sporns, 2010). Thus, functional connectivity analysis is a measure, which enables to 
quantify the level of the functional connections between brain regions.  As discussed by 
Bosboom et al. (2009), when performing connectivity analyses, we assume that two 
dynamically active neural networks are designated “A” and “B”. Time series “ai” and “bi”, 
using EEG signals from both networks, are recorded. The main purpose is to analyze the 
functional relation between “A” and “B” from “ai” and “bi” and to quantify the level of this 
relation. This quantification is performed with both linear and non-linear methods. Linear 
approaches in connectivity analysis assumes that the more “ai” and “bi” corresponds to 
each other, the stronger is the relation between “A” and “B”. In this way, for instance, the 
coherence is calculated as an estimate of a function of frequency between two signals 
(Schoffelen and Gross 2009). In contrast to coherence, where the stability of the phase 
relation between two signals is assessed and taken as an indicator of synchronization 
between the brain regions, the global field synchronization (GFS) makes no assumption 
about the spatial location of the activity (Koenig et al., 2001, 2005). GFS is calculated as a 
function of all frequency bands.  
However, there can be a functional relation between the structures “A” and “B” even if 
time series “ai” and “bi” do not correspond to each other; in this case non-linear methods 
of analysis are applied. One of these methods is synchronization analysis, which implies 
that “the state of A is a function of the state of B” (Stam et al., 2007).  Synchronization 
Likelihood (SL) is an estimate of synchronization, which reflects dynamic interactions of 
the chaotically active coupled networks. SL denotes how strongly a signal channel at a 
given time is synchronized to other channels. Another estimate of synchronization is 
Phase Lag Index (PLI). PLI is calculated from the asymmetry of the distribution of 
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instantaneous signal phase differences between two brain regions and has the advantage 
of being free of effects of volume conduction as opposed to the methods mentioned before. 
In other words, PLI reflects the degree of synchronization between couples of signals. 
After characterization of single connections, the next level of connectivity analysis 
consists in description of the whole network, applying graph theory method. In this 
method functional connections between brain structures are described as graphs 
(networks) (Watts and Strogatz 1998). These graphs consist of vertices (nodes) and 
corresponding sets of edges (connections). There are different approaches to assess the 
obtained graph: e.g. weighted graph analysis and minimum spanning tree. The two 
fundamental measures of weighted graph are: Clustering Coefficient (CC) and Path Length 
(PL). Olde Dubbelink et al., (2014b) describe CC as an estimate of “the likelihood that 
neighbors of a vertex are also connected to each other, and characterizes the tendency to 
form local clusters”.  In other words CC describes local “connectedness”. The same author 
described PL as a “measure for global integration of the network. It is defined as the 
harmonic mean between all possible vertex pairs in the network, where the shortest path 
between two vertices is defined as the path with the largest total weight”. Thus PL 
describes global “connectedness”. 
Graphs may be very complex and large, forming a variety of nodes and paths. A 
subgraph can be developed which connects all nodes through the shortest paths without 
forming cycles; such subgraph is referred to as minimum spanning tree of a weighted 
graph (Stam et al., 2014). The following measures are used for minimum spanning tree 
estimation: leaf number (the number of nodes with only one edge), eccentricity of a node 
(the length of the longest connection from this node to any other node), betweenness 
centrality of a node (the fraction of all connections in the tree that include, but do not stop 
at, that node), and tree hierarchy (a quotient of the leaf number to the product of twice 
the number of edges to the highest betweenness centrality of any node in the tree). These 
measures estimate the complexity of connections in the topographical brain network.  
Reliability of the qEEG analysis: individual variability 
According to Näpflin et al. (2007) inter-individual variability of absolute power of the 
traditional frequency bands in healthy humans is large, while intra-individually the power 
spectrum remains stable over a period of 12 to 40 months in healthy individuals. 
However, interpretation of a change in relative power in an individual is ambiguous and 
requires knowledge of more information than a change in absolute power. For example a 
decrease of the relative alpha power can be due to either a decrease of absolute alpha 
power but also to an increase of the absolute power in one or more of the other frequency 
bands without any change in the absolute alpha power, or to a combination of both.  In 
cross-sectional comparisons of small groups of individuals, alterations in relative power 
are more easily detected than changes in absolute power, while absolute power is a good 
measure for longitudinal, intra-individual changes or cross-sectional comparisons of very 
large populations. Derived indices were proposed as a possible solution for the problem 
that exists in relative power relationship between frequency bands: spectral ratio (sum 
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of alpha and beta powers divided by the sum of delta and theta powers) (Morita et al., 
2011), or alpha/theta ratio (Gu et al., 2016). 
Test-retest effect 
According to consecutive reports EEG frequency parameters are stable over time. 
Gasser et al., (1985) were amongst the first to address the issue of test-retest reliability of 
qEEG parameters. They reported that alpha electrical activity of the brain cortex showed 
the best reliability and delta and beta activity had the worst reliability. Dustman et al., 
(1999) investigated the variability of absolute and relative powers in five frequency bands 
– delta, theta, alpha, beta, and gamma – over the interval of 6 months in a sample of 222 
males aged from 4 to 90 years. Age-related dependence of the parameters was identified, 
but the frequency markers, especially power in the alpha band, showed a satisfactory 
reliability over time. Later, Näpflin et al., (2007), in above mentioned study, replicated 
these results in healthy adults. Additionally, the qEEG frequency markers are not 
influenced by cognitive activity. Grandy et al., (2013) investigated the modifiability of the 
alpha frequency of healthy subjects before and after a series sessions of cognitive tasks. 
Cognitive tasks had no significant effects on the resting state peak alpha frequency 7.5 – 
12.5 Hz. 
Influence of dopamine-replacement therapy on qEEG parameters 
The effects of levodopa and dopaminergic medication on the EEG activity of the 
patients yielded ambiguous results: while some researchers reported that patients in a 
medicated and a non-medicated state revealed no influence of dopamine-replacement 
therapy on frequency characteristics (Stoffers et al., 2007; Moazami-Goudarzi et al., 2008), 
various other studies reported that levodopa treatment of PD induces an increase in alpha 
and beta bands, and a decrease of theta and delta bands. These latter changes are referred 
to as “activation” of EEG (Gironell et al., 1997).  George et al. (2013) analyzed the EEG 
power spectra and connectivity in non-demented PD patients in ON- and OFF-medication 
state, in both resting state and during a cognitive task. These results were compared to 
those of a group of healthy controls. No significant changes in powers were identified in 
relation to medication. Despite that fact, the authors showed that dopaminergic 
medication reduced the pathological synchronization in the beta band in the resting state, 
and induced task-related increase of beta power. These findings were consistent with the 
previous reports (Brown 2007; Stoffers et al., 2008). According to other researchers 
levodopa treatment has influence on functional brain connectivity assessed by MEG and 
these changes were mostly identified in beta frequency range. (Stam 2010). Therefore, 
studies of beta activity require adjustments according to dopaminergic stimulation while 
data with alpha and theta activity is probably largely independent from dopaminergic 
influence. 
 
 
Figure 6. Overview of risk factors for Parkinson disease dementia. 
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Three different categories of risk factors for Parkinson disease dementia (PDD) — clinical, molecular, and 
structural/functional imaging — are illustrated. Factors with evidence from longitudinal studies are shaded 
pink, and factors with evidence from cross-sectional studies are shaded grey. Interrelationships between 
factor categories (bidirectional arrows) and temporal relationships between cross-sectional factors and PDD 
(unidirectional arrows) remain unclear. MCI, mild cognitive impairment; MEG, magnetoencephalogram. 
With permission from Nature Publishing Group (source: Aarsland et al, 2017) 
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Chapter 4. Quantitative EEG markers of dementia in Parkinson’s 
disease (systematic review)  
 
As discussed in Chapter 3, quantitative EEG has shown good potential in identification 
of cognitive deterioration in patients with PD. Quantitative EEG is advancing fast, and 
various new methods have been introduced and applied in qEEG research. In this review, 
we analyzed recent publications addressing its predictive value for detecting of PD related 
worsening of cognition.  
Methods of literature search 
References for this review were identified through search of the MEDLINE database 
(Panel 2). The following search strategy was used: ((((eeg) AND parkin*))) AND 
("2005"[Date - Publication]: "2015"[Date - Publication]). 739 potentially eligible 
publications were identified with this search query on March 2nd 2015.  
Panel 2. Selection of the publications 
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The titles and abstracts were examined for selection criteria:  
a) full text available in English;  
b) original research studies; 
c) subjects of the study: patients with PD, who were assessed by qEEG (spectral or/and connectivity 
analysis) and had not undergone deep brain stimulation;  
d) qEEG variables acquired through conventional EEG machines or MEG in resting state eyes-closed 
conditions in “ON” or/and “OFF” levodopa medication condition;  
e) studies focusing on comparison between groups of PD patients with different states of cognition (e.g. 
PD-D vs. PD-MCI) or/and longitudinal qEEG evaluations of cognition in patients with PD or/and 
evaluations of correlation of qEEG variables with tests and tools for cognitive assessment.  
Sixty one papers original research papers were identified after analysis of the titles and 
abstracts, and subject to full text analysis. After analysis of the full text, 24 original 
research publications in peer-reviewed journals were selected for the final analysis 
(Table 6).  
 
Analysis of the findings 
These studies were performed by ten independent research groups. Independence of 
the authors was analyzed by reviewing the affiliations of the first and the corresponding 
authors. Details summarizing the profiles of the included publications are shown in Table 
6. Profiles of the excluded papers are shown in Supplement 1. 
Table 6. Profiles of the studies, which met the inclusion criteria. 
AD – Alzheimer’s disease; DLB – dementia with Lewy bodies; HC – healthy controls; PD-D – Parkinson’s disease with 
dementia; PD-MCI– Parkinson’s disease with mild cognitive impairment; PDNC - Parkinson’s disease with normal cognition; 
PDwD – Parkinson’s disease without dementia (no information on MCI). 
No Author(s) Type of the study/setting;  Analyzed parameter(s) Affiliation of the 
corresponding 
author 
Studies with EEG with 10-20 international system 
1 Caviness et al. 
2007 
comparison of 8 PD-D vs.16 PD-MCI 
vs. 42 PDNC 
Relative spectral power Mayo Clinic, 
Scottsdale, USA 
2 Bonnani et al. 2008 observation of 36 LBD, 19 PD-D 
without cognitive fluctuations, 16 PD-
D with cognitive fluctuations, 17 AD 
and 50 HC 
Compressed spectral 
arrays and relative 
spectral power 
University G. 
d’Annunzio of 
Chieti-Pescara, 
Pescara, Italy 
3 Fonseca et al. 2009 comparison of 7 PD-D vs. 10 PD-MCI 
vs. 15 PDNC vs. 26 HC 
Relative and absolute 
amplitudes 
Pontificia 
Universidade 
Catolica de 
Campinas, 
Campinas, Brazil 
4 Kamei et al. 2010 comparison of PD patients with 
executive dysfunction vs. 25 PD 
patients without executive 
dysfunction. 
Absolute spectral power  Nihon University 
School of Medicine, 
Tokyo, Japan 
5 Babiloni et al. 2011 comparison of 13 PD-D vs. 20 AD vs. 
20 HC 
Spectral and source 
analyses 
Casa di Cura San 
Raffaele Cassino, 
Italy 
6 Klassen et al. 2011 observation of 106 PD-wD 
 
Relative spectral power Mayo Clinic, 
Scottsdale, USA 
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7 Morita et al. 2011 comparison of 100 PD: 43 with MMSE 
28-30 vs. 35 with MMSE 24-27 vs. 22 
with MMSE <24 
Absolute spectral power Nihon University 
School of Medicine, 
Tokyo, Japan 
8 Pugnetti et al. 
2010 
comparison of 21 PDwD vs. 7 PD-D 
vs. 10 LBD vs. 14 HC. 
Global field 
synchronization  
Scientific Institute S. 
Maria Nascente, 
Milan, Italy 
9 Fonseca et al. 2013 comparison of 12 PD-D vs.31 PDwD 
vs. 38 AD vs. 37 HC 
Absolute spectral power 
and coherence 
Pontificia 
Universidade 
Catolica de 
Campinas, 
Campinas, Brazil 
10 Gu et al. 2016 observation of 
9 PD-D and 17 PD-MCI 
Relative and absolute 
spectral power 
Nanfang Hospital, 
Guangzhou, China 
11 Caviness et al. 
2015 
observation of 71 PDwD Relative spectral power Mayo Clinic, 
Scottsdale, USA 
12 Fonseca et al. 2015 comparison of 31 PDwD vs. 28 AD vs. 
27HC 
Absolute spectral power 
and coherence 
Pontificia 
Universidade 
Catolica de 
Campinas, 
Campinas, Brazil 
Studies with EEG with 256 channels 
13 Benz et al. 2014 comparison of 20 PD-MCI vs. 20 PD-D 
vs. 20 AD vs. 20 HC 
Relative spectral power Hospitals of the 
University of Basel, 
Basel, Switzerland 
14 Bousleiman et al. 
2014 
comparison of 12 PDNC vs. 41 PD-
MCI 
Relative spectral power Hospitals of the 
University of Basel, 
Basel, Switzerland 
15 Zimmermann et al. 
2015 
analysis of 48 PDwD Median background 
frequency 
Hospitals of the 
University of Basel, 
Basel, Switzerland 
 
Studies with 151-channel whole-head MEG 
16 Bosboom et al. 
2006 
comparison of 13 PD-D vs. 13 PDwD 
vs. 13 HC 
 
Relative spectral power VU University 
Medical Center, 
Amsterdam, the 
Netherlands 
17 Stoffers et al. 2007 comparison of 70 PDwD vs. 21 HC Relative spectral power VU University 
Medical Center, 
Amsterdam, the 
Netherlands 
18 Stoffers et al. 2008 comparison of 70 PDwD vs. 21 HC Synchronization 
likelihood 
VU University 
Medical Center, 
Amsterdam, the 
Netherlands 
19 Bosboom et al. 
2009 
comparison of 13 PD-D vs. 13 PDwD Synchronization 
likelihood  
VU University 
Medical Center, 
Amsterdam, the 
Netherlands 
20 Ponsen et al. 2013 comparison of 
13 PD-D vs. 13 PDwD 
Relative spectral power 
and phase lag index  
VU University 
Medical Center, 
Amsterdam, the 
Netherlands 
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21 Olde Dubbelink et 
al. 2013a 
observation of 
49 PDwD and 14 HC 
 
Relative spectral power VU University 
Medical Center, 
Amsterdam, the 
Netherlands 
22 Olde Dubbelink et 
al. 2013b 
observation of 
43 PDwD and 14 HC 
 
Phase lag index VU University 
Medical Center, 
Amsterdam, the 
Netherlands 
23 Olde Dubbelink et 
al. 2014b 
observation; 
63 PDwD  
Weighted graph and 
minimum spanning tree  
VU University 
Medical Center, 
Amsterdam, the 
Netherlands 
24 Olde Dubbelink et 
al. 2014a 
observation of 
43 PDwD and 14 HC 
 
Relative spectral power VU University 
Medical Center, 
Amsterdam, the 
Netherlands 
 
In spite of a common concept – applying qEEG methods to investigate cognition of 
patients with PD – these studies were too heterogeneous in terms of applied methods. The 
researchers use different methods of mathematical processing of the EEG, different 
approaches (such as spectral or connectivity analysis), and different settings. While  there 
is a more or less common consensus regarding diagnostic criteria of an advanced 
cognitive deterioration – PD-D, such a consensus regarding diagnostic criteria for 
intermediate (between normal cognition and PD-D) cognitive disorder – mild cognitive 
impairment – is still under discussion (Winblad et al., 2004; Palmer and WInblad, 2007; 
Ganguli et al., 2011). Due to these differences a full meta-analysis was not performed. 
However, the effect sizes of the reported variables were calculated in order to compare 
the relevant results. The effect size is a statistical measure, reflecting how much two 
standardized means are different between two populations (Kelley and Preacher, 2012). 
The larger the effect size is, the more two populations are distinct in a studied parameter. 
Similarly, correlation coefficients were analyzed by Fisher's Z transformation (Cox, 2008). 
In this case, the larger the Fisher’s Z is, the stronger is the correlation. 
 
Spectral characteristics of cognitive states in Parkinson’s disease 
Global power spectra 
Seventeen studies focused on spectral features of cognitive states in PD. Six of these 17 
studies focused on the capacity of discrimination between better and worse states of 
cognition in PD (e.g. group of patients with PD-MCI vs. group with PD patients with normal 
cognition (PDNC); or group with PD-MCI vs. group with PD-D) (Table 7). Global delta and 
theta powers (these variables were increased in PD-D patients) and peak background 
frequency (decreased in PD-D patients) had the largest effect sizes to discriminate PDNC 
vs. PD-D. Global delta power (increased in PD-D patients), peak background frequency 
and global alpha power (decreased in PD-D patients) had the largest effect sizes to 
distinguish PD-MCI vs. PD-D.  Additionally, beta peak frequency was significantly 
increased (p<0.01), and global alpha power and alpha/theta ratio were significantly 
decreased (p<0.01 and p<0.01) in PD-D vs. PD-MCI in one report (although original data 
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was not available) (Gu et al., 2016). Global alpha power, peak background frequency 
(decreased in PD-MCI patients) and global theta power (increased in PD-MCI patients) 
had the largest effect sizes to discriminate PDNC vs. PD-MCI.  
Table 7. EEG and MEG spectral markers which significantly discriminate between cognitive 
states in PD 
1 original data not available, effect size and confidence intervals estimated using p value conversion; 
2 the study is longitudinal; only assessment on admission is shown in this table; 
3 age for groups of the patients not available, age of the combined sample is shown; 
4 mean age not available, mean age calculated from median and range according to Hozo et al., 2005 
 
CAF – Clinical Assessment of Fluctuations; DF – dominant frequency; DFV – dominant frequency 
variability;DSM-IV - Diagnostic and Statistical Manual of Mental Disorders IV; GRP – global relative power; 
MCI – mild cognitive impairment; PD – Parkinson’s disease; PDNC – Parkinson’s disease without cognitive 
impairment; PD-MCI – Parkinson’s disease with mild cognitive impairment; PD-D – Parkinson’s disease with 
dementia; PDwD – Parkinson’s disease without dementia; PD-DnF – Parkinson’s disease with dementia 
without cognitive fluctuations; PD-DF -  Parkinson’s disease with dementia with cognitive fluctuations. 
Author(s) Diagnostic 
groups of 
patients with 
PD (N) 
Mean age 
(years) 
Evaluative tests: 
cognitive 
pathology 
(criteria) 
Parameter(s) showed significant 
difference between the groups 
with PD 
Effect size (95% CI) 
 
 
 
Bosboom 
et al. 2006 
PD-D (13) 
PDwD (13) 
 
74.4 
71.7 
 
Dementia (DSM-IV)  GRP delta (0.5-4 Hz) and GRP theta 
(4-8 Hz)1 
PDwD vs. PD-D 
1.47 (0.60, 2.34) 
GRP alpha (8-13 Hz) and GRP beta 
(13-30 Hz)1 
PDwD vs. PD-D 
-1.47 (-2.34, -0.60) 
GRP gamma (30-48 Hz)1 PDwD vs. PD-D 
-1.47 (-2.34, -0.60) 
Caviness 
et al. 2007 
PD-D (8) 
PD-MCI (16) 
PDNC (42) 
78.0 
80.4 
74.6 
Dementia (DSM-
IV); 
MCI (Petersen et al. 
1999)  
GRP delta (1.5-3.9 Hz)  PDNC vs. PD-MCI 
0.11 (-0.47, 0.68) 
PD-MCI vs. PD-D 
1.27 (0.35, 2.19) 
PDNC vs. PD-D 
1.46 (0.67, 2.29) 
GRP theta (4-7.9 Hz) PDNC vs. PD-MCI 
0.75 (0.16, 1.34) 
PD-MCI vs. PD-D 
0.38 (-0.46, 1.24) 
PDNC vs. PD-D 
1.37 (0.57, 2.17) 
GRP alpha (8-12.9 Hz) PD-MCI vs. PD-D 
-0.86 (-1.75, 0.01) 
PDNC vs. PD-D 
-1.01 (-1.79, -0.22) 
GRP beta1 (13-19.9 Hz) PDNC vs. PD-MCI 
-0.63 (-1.21, 0.04) 
PD-MCI vs. PD-D 
-0.70 (-1.57, 0.17) 
PDNC vs. PD-D 
-1.16 (-1.95, -0.37) 
GRP beta2 (20-30 Hz). PDNC vs. PD-MCI 
-0.57 (-1.15, 0.02) 
PD-MCI vs. PD-D 
-0.81 (-1.69, 0.07) 
PDNC vs. PD-D 
-1.21 (-2.00, -0.41) 
Peak frequency at locations P3, P4 
and Oz 
PDNC vs. PD-MCI 
-0.90 (-1.51, -0.31) 
PD-MCI vs. PD-D 
-0.99 (-1.88, -0.10) 
PDNC vs. PD-D 
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Patients with PD-D were compared to PD patients without dementia in two studies 
(Bosboom et al., 2006; Fonseca et al., 2013). The latter group might include both PDNC and 
PD-MCI. However, global delta and theta powers (increased in PD-D patients) had the 
largest effect sizes. In one study, two sub-groups of PD-D patients were compared: 
patients with PD-D and cognitive fluctuations and patients with PD-D without cognitive 
fluctuations (Bonnani et al., 2008). Cognitive fluctuations are described as disorders of 
consciousness ranging from reduced arousal to stupor (McKeith et al., 1996). Global alpha 
and the so-called “pre-alpha” (5.6-7.9 Hz) powers had the largest effect sizes: alpha was 
decreased and “pre-alpha” increased in demented patients with cognitive fluctuations. 
Topographic distribution of power spectra 
Topographic distribution of spectral powers was addressed in 7 studies (Morita et al., 
2011; Bosboom et al., 2006; Bonanni et al., 2008; Bousleiman et al., 2014; Fonseca et al., 
2009; Kamei et al., 2010; Ponsen et al., 2013). Theta and alpha powers in temporal and 
parietal regions bilaterally had the largest effect sizes to distinguish between PDNC and 
PD-D patients. Theta power was increased and alpha power decreased in PD-D patients. 
Spectral ratio (sum of alpha and beta powers divided by the sum of delta and theta 
powers) in frontal regions and delta and alpha powers in posterior derivations had the 
largest effect sizes to distinguish between PD-MCI and PD-D. Delta power was increased 
and alpha power and spectral ratio were decreased in PD-D patients. Theta and beta 
powers and spectral ratio in posterior derivations had the largest effect sizes to 
distinguish between PDNC and PD-MCI. Theta power was increased and alpha power was 
decreased in PD-MCI patients. In one study PD patients with executive dysfunction were 
-1.88 (-2.54, -1.20) 
Bonanni 
et al. 
20082 
 
PD-DnF (19) 
PD-DF (16) 
70.03 PD-D (history of PD 
preceded dementia 
for at least 24 
months);  
Cognitive 
fluctuations (CAF, 
Walker et al. 2000) 
GRP theta (4.0-5.5 Hz) PD-DnF vs. PD-DF 
2.82 (1.88, 3.75) 
GRP pre-alpha (5.6-7.9 Hz) PD-DnF vs. PD-DF 
5.26 (3.86, 6.67) 
GRP alpha (8.0-12.0 Hz) PD-DnF vs. PD-DF 
-8.40 (-10.47, -6.32) 
Mean frequency PD-DnF vs. PD-DF 
-0.93 (-1.64, -0.24) 
DF in parieto-occipital derivations PD-DnF vs. PD-DF 
-1.18 (-1.90, -0.46) 
DFV in parieto-occipital derivations PD-DnF vs. PD-DF 
1.19 (0.47, 1.91) 
 
 
Fonseca et 
al. 2013 
PD-D (12) 
PDwD (31) 
 
70.3 
68.1 
Dementia (Dubois 
et al. 2007) 
Mean absolute power delta (0.8-3.9 
Hz) 
PDwD vs. PD-D 
0.85 (0.16, 1.54) 
Mean absolute power theta (4.29-
7.8 Hz) 
PDwD vs. PD-D 
1.23 (0.52, 1.94) 
Bousleima
n et al. 
2014 
PD-MCI (41) 
PDNC (12) 
67.23 MCI (Litvan et al. 
2012). 
GRP alpha1 (8-10 Hz) PDNC vs. PD-MCI 
-0.82 (-0.131, -0.001) 
Gu et al. 
20162 
PD-D (9) 
PD-MCI (17) 
 
56.74 
62.14 
Dementia (DSM-
IV); 
MCI (Petersen et al. 
1999) 
Beta (13-30 Hz) peak frequency1 
 
PD-MCI vs. PD-D 
1.10 (0.27, 1.92) 
GRP alpha (8-13 Hz)1 
 
PD-MCI vs. PD-D 
-1.10 (-1.92, -0.27) 
alpha/theta ratio1 - alpha (8-13 Hz) 
divided by theta (4-7 Hz)  
PD-MCI vs. PD-D 
-1.10 (-1.92, -0.27) 
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compared to PD patients without executive dysfunction (Kamei et al., 2010). The largest 
effect size had spectral ratio in frontal derivations; spectral ratio was decreased in 
patients with executive dysfunction. Additionally, in one study PD-D patients were 
compared with PD without dementia (Bosboom et al., 2006). The largest effect sizes had 
alpha and delta powers in temporal, parietal and occipital regions, and beta and delta 
powers in central regions, and beta, alpha and delta powers in frontal regions. Delta 
power was increased, and alpha and beta powers were decreased in PD-D patients. 
Additionally, “pre-alpha” in frontal, temporal and parieto-occipital derivations had the 
largest effect size for distinguishing PD-D patients without cognitive fluctuations from PD-
D patients with cognitive fluctuations (Bonanni et al., 2008).  “Pre-alpha” power was 
increased in patients with cognitive fluctuations. 
Correlation of power spectra with cognitive assessment tools 
Correlation of spectral powers with different cognitive assessment tools and tests was 
analyzed in seven studies (Table 8). The mostly used tool for cognitive assessment  in 
these studies was Mini-Mental State examination (MMSE). Positive Fisher’s Z was 
observed for MMSE and spectral ratios at all scalp locations, and relative power in the 
range 8-13 Hz (alpha), and peak background frequency; while negative Fisher’s Z was 
observed for MMSE and relative power in the range 0-4 Hz (delta). Negative Fisher’s Z 
was observed for Cambridge Cognitive Examination (CAMCOG) and relative power in the 
range 4-8 Hz (theta) in bilateral occipital and right temporal regions. Additionally, in one 
study, correlation of median frequency with cognitive domains was investigated 
(Zimmermann et al., 2015). Significant correlations were observed for “episodic and long 
term memory domain”, followed by “overall cognitive score”, “fluency domain”, “attention 
domain” and “executive functions domain”. In one study no correlation of absolute power 
spectra with neuropsychatric inventory was reported in non-demented PD patients 
(Fonseca et al., 2015). 
 
Table 8. Markers which significantly correlate with various cognitive assessment tools in PD. 
*Original data not available in the publications. Fisher’s Z calculated from correlation coefficient and 
sample size, according to Lipsey and Wilson 2001 (Practical Meta-Analysis (Applied Social Research 
Methods) 1st Edition). 
**Spectral ratio - sum of absolute power values for alpha (8.20-12.89 Hz) and beta (13.28-30.8 Hz) waves 
divided by the sum of absolute power values for delta (1.17-3.91 Hz) and theta (4.3-7.81 Hz) 
***Cognitive domain – combined parameter, including a set of cognitive tests, which indicates cognitive 
performance in certain categories. 
****Combined score, including an average of 26 cognitive tests’ results 
CAMCOG - Cambridge Cognition Examination; MMSE – Mini Mental State Examination. 
 
Refs Age, 
mea
n 
N Correlation Fisher’s z (95% CI) 
Bosboom 
et al. 2006 
71.7 13 
PD-wD 
Left occipital theta (4-8 Hz) vs. CAMCOG 
 
-0.70 (-1.32, 0.08) 
Right occipital theta (4-8 Hz) vs. CAMCOG 
 
-0.67 (-1.29, 0.05) 
Right temporal theta (4-8 Hz) 
 
-0.68 (-1.30, 0.06) 
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Caviness 
et al. 2007 
76.4 66 PD-wD GRP delta (1.5-3.9 Hz) vs. MMSE 
 
-0.51 (-0.76, -0.26) 
GRP alpha (8-12.9 Hz) vs. MMSE 
 
0.34 (0.10, 0.59) 
Peak background frequency vs. MMSE 
 
0.42 (0.18, 0.67) 
Stoffers et 
al. 2008 
59.4 18 de 
novo PD 
Relative low alpha (8-10 Hz) vs. redundancy of the second order (Vienna 
perseveration) in bilateral central and parietal regions  
-0.11 (-0.19, -0.01) 
Morita et 
al. 2011 
67.6 100 PD Spectral ratio** at Fp location (electrode positions Fp1 and Fp2) vs. 
MMSE 
 
0.30 (0.10, 0.50) 
Spectral ratio** at F location (electrode positions F3, F4, F7 and F8) vs. 
MMSE 
0.32 (0.12, 0.52) 
Spectral ratio** at C location (electrode positions C3 and C4) vs. MMSE 0.28 (0.08, 0.48) 
Spectral ratio** at P location (electrode positions P3 and P4) vs. MMSE 0.32 (0.12, 0.52) 
Spectral ratio** at T location (electrode positions T3, T4, T5 and T6) vs. 
MMSE 
0.32 (0.12, 0.52) 
Spectral ratio** at O location (electrode positions O1 and O2) vs. MMSE 0.35 (0.16, 0.55) 
Babiloni 
et al. 2011 
72.0 13 
PD-D 
Relative alpha1 (8-10.5 Hz) in parietal regions (Brodman areas 5, 7, 30, 
39, 40, 43) vs. MMSE 
0.35 (-0.27, 0.97) 
Relative alpha1 (8-10.5 Hz) in occipital regions (Brodman areas 5, 7, 30, 
39, 40, 43) vs. MMSE 
0.44 (-0.18, 1.05) 
Fonseca 
et al. 2015 
68.8 31 
PD-wD 
Absolute powers: delta (0.8-3.9 Hz), theta (4.29-7.8 Hz), alpha (8.2-12.5 
Hz) and beta (12.9-36.3 Hz) vs. Neuropsychiatric inventory 
No significant 
correlation with any 
marker 
 
Zimmerm
ann et al. 
2015 
67.6 48 
PD-wD 
Median frequency vs. Episodic Long term memory cognitive domain*** 0.60 (0.31, 0.90) 
Median frequency vs. Overall Cognitive score**** 0.51 (0.22, 0.80) 
Median frequency vs. Fluency cognitive domain*** 0.41 (0.12, 0.70) 
Median frequency vs. Attention cognitive domain*** 0.39 (0.10, 0.68) 
Median frequency vs. Executive cognitive domain*** 0.35 (0.06, 0.65) 
 
 Additionally, longitudinal correlation of frequency results with cognitive states in PD 
using tools for cognitive assessment was assessed in 3 studies (Bonanni et al., 2008; Olde 
Dubbelink et al., 2013a; Caviness et al., 2007). In the first study (Bonanni et al., 2008), 
correlation with Frontal Assessment Battery scores was investigated: negative Fisher’s Z 
was observed for power in the range 8-12 Hz (alpha), and positive Fisher’s Z - for powers 
in the range 4-8 Hz (theta), over 2 years. In the second study (Olde Dubbelink et al., 2013a), 
various tools for cognitive assessment correlated with power spectra over 7 years of 
observation: negative Fisher’s Z was observed: for global relative powers in the range 0.5-
4 Hz (delta) and CAMCOG and Spatial Span Test; and for GRP in the range 4-8 Hz (theta) 
and CAMCOG, Pattern Recognition Memory, Semantic Fluency Test, and Spatial Span Test; 
and for GRP in the range 8-10 Hz (alpha1) and Spatial Working Memory. Positive Fisher’s 
Z was observed: for powers in the range 8-13 Hz (alpha1 and alpha2) and 30-48 Hz 
(gamma) and CAMCOG, Pattern Recognition Memory and Spatial Span Test; and for 
powers in the range 4-8 Hz (theta) and Spatial Working Memory. In the third study 
(Caviness et al., 2007), correlation with power in the range 2.5-4 Hz (delta) was 
investigated: negative Fisher’s Z was observed for MMSE, Rey Auditory Verbal Learning, 
Controlled Oral Word Association Test and Stroop test; while positive Fisher’s Z was 
observed for Clinical Dementia Rating Sum of Boxes and Functional Assessment Staging 
Tool. 
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Hazard of conversion to dementia in Parkinson’s disease 
The relation of power spectra to conversion to PD-D was examined in 3 studies (Table 
9). Hazard ratios of conversion to PD-D were analyzed in 2 studies. The hazard ratio of 
conversion to PD-D was significantly higher for patients with background EEG frequency 
below the median value of the entire sample at baseline (Klassen et al. 2011), and the theta 
power above the median value of the entire sample at baseline (Olde Dubbelink et al. 
2014a). In one study, patients with PD-MCI, who converted to PD-D over two years had 
increased beta peak frequency, and decreased alpha relative power and alpha/theta ratio 
at baseline (Gu et al. 2016). 
Table 9. Prediction of conversion to PD-D with spectral EEG markers 
Author(s) Duration of 
observation 
Rates of conversion to PD-D over 
time 
Hazard 
Klassen et al. 2011 0.31 to 8.8 
years with a 
mean of 3.3 
years 
The incidence of PD-D was 
calculated using the Kaplan-Meier 
method. The incidence of PD-D 
within 5 years of the baseline EEG 
examination was 34%. 
Incidence of dementia 
within 5 years was: 66% 
for patients with 
background rhythm 
frequency below median 
of 8.5, 51% for patients 
with theta power above 
median of 19. 
Gu et al. 2016 2 years 6 patients with PD-MCI converted to 
PD-D over a 2 year period 
At baseline assessment 
beta peak frequency was 
significantly increased 
in the converted 
patients, and alpha 
relative power and 
alpha/theta ratio were 
significantly decreased. 
Olde Dubbelink et 
al. 2014a 
7 years 19 PD patients without dementia 
converted to PD-D over a 7 year 
period 
At baseline assessment 
beta power was below 
median value of 27.96, 
peak frequency was 
below median value of 
8.39, and theta power 
was above median of 
22.85. 
 
Brain functional connectivity and cognitive states in Parkinson’s disease 
Seven studies focused on functional connectivity features of cognitive states in PD 
(Bosboom et al., 2009; Olde Dubbelink et al., 2014b, 2013b; Stoffers et al., 2008; Fonseca et 
al., 2013; Ponsen et al., 2013; Pugnetti et al., 2010). Global field synchronization (GBS) was 
addressed in one study and coherence in another one. Patients with PD-D were compared 
with PD patients without dementia in both studies. PD-D patients had significantly higher 
GBS in theta frequency range (p<0.02) and lower GBS in the alpha1 range (p<0.02) 
(Pugnetti et al., 2010); higher frontal interhemispheric (F3-F4) and higher fronto-occipital 
intrahemispheric (F3-O1; F4-O2) coherence in in the beta frequency band was observed 
in another study (Fonseca et al., 2013).  
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In two studies SL was investigated. In one study correlation of connectivity markers 
with cognitive tests in PD patients without dementia and with varying disease duration 
was investigated (Stoffers et al., 2008). Higher level of perseveration executive task in 
patients with recently diagnosed PD (in the last 6 months before participation in the 
study) was associated with increased interhemispheric SL in alpha1 band. In an 
exploratory study by Bosboom et al. (2009) PD-D patients were compared to non-
demented PD patients. Patients with PD-D had lower inter-hemispheric SL between 
temporal regions (frequency ranges: 0.5-4 Hz, 4-8 Hz and 8-10 Hz) and parietal regions 
(30-48 Hz); lower intra-hemispheric SL between frontal and temporal, and frontal and 
parietal regions in the left hemisphere (8-13 Hz), and frontal and temporal regions in the 
right hemisphere (8-13 Hz and 13-30 Hz). At the same time, higher intra-hemispheric SL 
was found between occipital and temporal, and occipital and parietal regions in the left 
hemisphere (13-30 Hz), and between parietal and occipital regions in the right 
hemisphere (8-10 Hz).  
Phase Lag Index (PLI) was investigated in two studies. A comparison of PD-D patients 
with non-demented PD patients showed weaker PLI in fronto-temporal (0.5-4 Hz) and 
parieto-temporo-occipital (8-13 Hz) couplings in demented patients (Ponsen et al., 2013). 
In this study, general region-to-region connectivity was stronger in theta band and 
weaker in delta, alpha and beta bands in PD-D. A longitudinal observation of initially non-
demented PD patients showed correlation of worsening of CAMCOG performance with a 
decrease of PLI in frontal and temporal regions in frequency range 8-10 Hz (Olde 
Dubbelink et al., 2013b). Finally, a graph theory analysis of longitudinal connectivity 
changes of non-demented PD patients was performed in one study (Olde Dubbelink et al., 
2014b). Worsening of cognitive performance over time correlated with increase in 
eccentricity in the frequency range 8-10 Hz, and decrease of clustering coefficient and 
path length in the frequency range 4-8 Hz.  
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Chapter 5. Three-years follow up of patients with Parkinson’s disease 
(clinical study) 
 
 The purpose of our study was to investigate clinical and qEEG (spectral) 
parameters as PD-D predictors, using high-resolution EEG with 256 electrodes and with 
fully automated removal of artefacts (Hatz et al., 2015). Our hypothesis was that qEEG 
variables at baseline are able to predict PD-D, and these qEEG variables are not influenced 
by clinical and demographic parameters. To address this research question a prospective 
(3 years) cohort of PD patients was assessed for potential neurological, psychological and 
neurophysiological risk factors. 
Methods: enrollment of the patients 
Patients were recruited from the outpatient clinic of the Department of Neurology and 
Neurophysiology of the Hospital of the University of Basel (Basel, Switzerland) in the 
period 2011 to 2012. Selection criteria: PD according to Queen Square Brain Bank criteria 
(Hughes 1992). Patients were excluded if they had dementia (DSM-IV), history of stroke, 
epilepsy, multiple sclerosis and surgical interventions to the brain, insufficient knowledge 
of German language. Patients underwent neurological, cognitive and neurophysiological 
(qEEG) examinations on inclusion (baseline) and after a mean time of 36 months (follow-
up). Specialists who performed the assessment of the patients (neurologists, 
neuropsychologists and technicians) were unaware of the details of this study. 
Standard protocol approvals, registrations, and patient consents 
The research ethics committee of the cantons of Basel approved this study 
(Ethikkommission beider Basel, ref. No 135/11). All patients were fully informed of the 
nature of the study and provided written consent to participate. 
Neurological assessment  
Subsection III (motor examination) of the Unified Parkinson’s Disease Rating Scale 
(UPDRS-III) and Non-Motor Symptoms (NMS) scale were filled out. Levodopa daily 
equivalent dose of the antiparkinsonian medication (LED) was calculated (Tomlinson et 
al., 2010). Disease duration was assessed since the first symptoms of PD reported by the 
patient or caregiver. 
Cognitive assessment  
Cognitive evaluation was performed in individual sessions divided in three parts; each 
part with duration of approximately 90 minutes per day. The interval between the parts 
of each session was between 24 and 48 hours. MMSE and a battery of 14 cognitive tests 
were applied. Test variables were normalized with reference to a normative data base of 
604 healthy controls from the Memory Clinic, Felix Platter Hospital of Basel, Switzerland 
(Berres et al., 2000). Cognitive tests were grouped in 6 cognitive domains (Zimmermann 
et al., 2015): attention, executive functions, fluency, long-term memory, working memory 
and visual-spatial functions (Table 10). A score reflecting cognitive performance in each 
domain comprised mean of the constituent test variables. An overall cognitive score (OCS) 
comprised a mean of all 14 cognitive tests. PD-associated mild cognitive impairment (PD-
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MCI) was diagnosed under the MDS Task Force criteria (Litvan et al., 2012). Patients, who 
did not fit to the criteria of PD-MCI, were considered as cognitively normal (PDNC). Mood 
and behaviour was assessed with tests: Beck Depression Inventory version II (BDI-II), 
Obsessive-Compulsive Inventory (OCI), and compartment “Emotional well-being” of the 
Parkinson’s disease Questionnaire with 39 items (PDQ39-EWB).  
Table 10. Cognitive tests and cognitive domains. 
Domain Tests within a domain 
(1) Attention  Stroop Color-Word: time for color naming 
 Trail-Making: time for part A 
 Digit Span: correct backward 
(2) Executive functions  Trail-Making: time for part B divided by time for part A 
 Stroop Color-Word: time for interference task divided by time for 
color naming 
 Wisconsin Card Sorting: number of errors 
(3) Fluency  Phonemic verbal fluency: correct answers 
 Semantic verbal fluency: correct answers 
(4) Long-term memory  Verbal Learning – long-delayed recall 
 Verbal Learning – discrimination 
(5) Working memory  Corsi blocks: correct forward 
 Divided attention: omissions 
(6) Visual-spatial 
functions 
 Block design 
 Rey-Osterrieth complex figure copy 
 
Neurophysiological assessment  
Continuous EEG with 256 electrodes was recorded in relaxed eyes-closed state of the 
patients (Net Station 300; Electrical Geodesics, Inc). Electrode located at CZ was used as 
reference. The sampling rate was set at 1000 Hz, oscillations were filtered with 2500 
order least-square filter with band-pass 0.5 – 70 Hz, and notch 50 Hz. Spectral analysis 
was performed with „TAPEEG“ toolbox (Hatz et al., 2015) by Welch method (Welch, 1967). 
Detection and removal of artefacts (e.g. eye blinks) was fully automated, by an 
independent component analysis. Channels with bad activations were interpolated by 
spherical spline method. Global relative median power (GRMP) was calculated in 
frequency ranges: delta (1 – 4 Hz), theta (4 – 8 Hz), alpha1 (8 – 10 Hz), alpha2 (10 – 13 
Hz), and beta (13 – 30 Hz). Median frequency (MF) in the range 4 – 14 Hz was calculated 
from occipital electrodes as the 50% quantile of the power spectrum (Fig.7).  
Blood sampling and genotyping 
From each patients we collected 10 ml of intravenous blood. Ethylenediamine 
tetraacetic acid was added to blood as in vitro anticoagulant. Blood samples were frozen 
at -70 oC and then were sent via express shipping from the Hospital of the University of 
Basel to the Hertie Institute for Clinical Brain Research in Tübingen.  
 
DNA was extracted by salting-out and ethanol precipitation. 1.875 µg DNA of each 
sample was subsequently shipped on dry ice to the genotyping facility at the Helmholtz 
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center Munich. The samples were then genotyped with the NeuroChip.  This NeuroChip 
array was introduced in 2017 as a fast and efficient method for investigation of 
neurodegenerative diseases (Blauwendraat et al., 2017). TheNeuroChip backbone is 
based on a genome-wide genotyping array (Infinium HumanCore-24 v1.0) containing 
306,670 tagging single nucleotide polymorphisms (SNPs) and a custom content that has 
been updated and extended with neurodegenerative disease-related custom content 
consisting of 179,467 SNPs.  Of the variants, associated with neurodegenerative disorders, 
348 SNPs were related with PD. Among the latter the following : LRRK2 (n=80), PINK1 
(n=76), PARK2 (n=69), PARK7 (n=12), SNCA (n=5), other (n=106, including MAPT, GBA, 
APOE, COMT Intron rs2239393). 
The genetic analysis of our sample of patients will be finished in Spring or Summer 
2018. The results will be included in the cognitive risk score calculations and 
subsequently distributed as reports and publications. 
Statistics 
Statistical calculations were performed with R tool for statistical calculations v. 3.2.1.  
(R Core Team, 2015)The normality of the distribution of the data was tested with Shapiro-
Wilk test. The influence of the baseline parameters on cognitive state at follow-up was 
checked with univariate and multivariate linear regression models with backward 
elimination. Prediction accuracy was checked with Receiver Operating Characteristic 
(ROC) curves. The results were additionally checked with Random Forest method with 
regression. The level of statistical significance was set at 0.05. 
Figure 7. Electrode mapping of 256 electrodes.  
 
Active electrodes colored in dark and light gray, occipital electrodes – dark gray. 
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Cognitive outcome 
A change index in overall cognitive score (CI-OCS) was used as outcome. The CI-OCS 
was calculated as difference in overall cognitive score between follow-up and baseline, 
divided by the standard error of the difference (Jacobson and Truax, 1991). 
Regression Models 
The following baseline variables were considered as predictors: GRMP in ranges delta, 
theta, alpha1, alpha2, and beta, MF, cognitive domains: “attention,” “executive functions,” 
“fluency,” “long-term memory,” “working memory,” and “visual-spatial functions,” age, 
sex, highest educational level (measured in years), disease duration (years), duration of 
observation (years), LED, NMS,and UPDRS-III. Significant variables from the univariate 
regression models were included in multivariate models. To check the added value of the 
significant predictors to the cognitive task performance, non-normalized to 100% 
explained variance of the models was calculated. The relative importance of the variables 
was calculated with the R package “relaimpo” (Grömping, 2006) with method “LMG” and 
plotted in a bar diagram. 
ROC-Curves 
The ROC-curve analyses were performed with the R package “pROC” (Robin et al., 
2011). We categorized the sample on the basis of MMSE score at follow-up (cut off <24). 
Random Forest with regression 
Random Forest (Hastie et al., 2009) is an ensemble machine learning method used for 
classifying data with high accuracy and for regression analysis. The goal of this method is 
to reduce the variance in the data and get a higher predictive performance of the model. 
This is done by using several decision trees, which are constructed based on subsets of 
the same training data, and then getting predictions on the test set based on the training. 
Each variable included in the model is evaluated based on its effect on the overall accuracy 
of the model and is ranked higher up if its exclusion results in a drop in the model 
accuracy. The role of each variable in the classification process is reflected in output 
measures called mean decrease accuracy (MDA) and mean decrease gini coefficient 
(MDGC). MDA is the increase in mean squared error of predictions after predictor 
variables being randomly shuffled. Higher the MDA, the more important is the variable. 
MDGC relates to the decrease of node impurity in the decision tree after each split, 
summed over all splits and trees. Higher the MDGC is, the more important the variable. 
Random Forest analysis was performed with the R package “randomForest” (Liaw and 
Wiener, 2002). 
Results 
Enrollment of the Patients 
Between January 2012 and December 2013, 55 patients were selected in the study and 
assessed for neurological, psychological and qEEG parameters (Panel 3). At follow-up, 
cognitive outcome along with the other clinical data was obtained for 37 patients. Thus, 
these 37 patients were included in the analysis (Table 11).  
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Table 11. Sample at baseline. 
For continuous variables presented as median and range (M [min, max]). GRMP, global relative median 
power; PDQ39, Parkinson’s disease questionnaire with 39 items; UPDRS, unified Parkinson’s disease rating 
scale. 
Sex, males/females  25/12 
Age, years  67 [31, 84] 
Disease duration, years  8 [1, 20] 
Duration of observation, months  37 [30, 44] 
Education, years  14 [9, 20] 
Beck Depression Inventory-II  6 [0, 15] 
Obsessive Compulsive Inventory  6 [0, 25] 
PDQ39 – emotional well-being  17 [0, 50] 
UPDRS, Subscale III  14 [0, 50] 
Levodopa equivalent, mg per day  691 [150, 2129] 
Attention  -0.02 [-2.07, 1.13] 
Executive functions  0.03 [-3.73, 1.17] 
Fluency  -0.18 [-1.93, 1.61] 
Long-term memory  -0.13 [-1.62, 2.60] 
Working memory  -0.23 [-1.50, 2.37] 
Visual-spatial functions  -0.23 [-2.60, 1.79] 
Overall cognitive score  -0.10 [-2.05, 0.96] 
Mini Mental State  29 [24, 30] 
GRMP delta, %  22 [9, 42] 
GRMP theta, %  18 [10, 46] 
GRMP alpha1, %  18 [5, 33] 
GRMP alpha2, %  13 [5, 33] 
GRMP beta, %  20 [10, 38] 
Median frequency, Hz  8.71 [7.14, 9.99] 
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Panel 3. Flow chart  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Influence on CI-OCS 
Regression analyses (Tables 12.1-4) identified three baseline parameters which had 
significant influence on CI-OCS: GRMP theta (β = -3.16, p<0.001), cognitive domain 
“executive functions” (β = 0.54, p < 0.001), cognitive domain “working memory” (β = 0.19, 
p < 0.05), adjusted R squared  = 0.64, p < 0.001.  
Table 12.1. Univariate regression models. In all models, CI-OCS was introduced as 
dependent variable. 
Predictor Estimate Standard 
error 
Adj. R-
squared 
F-statistic t value p-value 
Age -0.020 0.013 0.075 3.897 -1.974 0.0563 
Sex (males) -0.360 0.174 0.083 4.256 -2.063 0.0505 
Education -0.008 0.024 0.117 3.440 -0.307 0.0519 
Duration of observation 0.037 0.286 -0.028 0.016 0.130 0.2575 
Disease duration -0.032 0.018 0.055 3.131 -1.770 0.0855 
UPDRS-III at baseline -0.017 0.009 0.067 3.590 -1.895 0.0664 
LED at baseline -0.000 0.000 -0.008 0.681 -0.826 0.4146 
Patients with parkinsonism 
screened in the out-patient 
clinic of the Hospital oft he 
University of Basel 
n=197 
Agreed to participate in the 
study and investigated at 
baseline  
n=55 
Investigated at follow-up 
n=37 
Patients with Parkinson’s 
disease who fit to the criteria 
of the study  
n=103 
Drop out from the study n=18: 
- lost contact n=8 
- refused to continue after DBS n=3 
- refused with unknown reason n=2 
- severe health problem (other than PD) n=2 
- refused due to change of residence n=2 
- death n=1 
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NMS at baseline -0.002 0.004 -0.019 0.328 -0.573 0.5704 
BDI-II at baseline -0.020 0.020 -0.001 0.930 -0.965 0.3414 
PDQ39EWB at baseline 0.000 0.006 -0.028 0.004 0.064 0.9495 
MMSE at baseline 0.030 0.073 -0.023 0.169 0.411 0.6834 
Attention at baseline 0.332 0.129 0.135 6.617 2.572 0.0145* 
Executive functions at 
baseline 
0.560 0.137 0.027 14.300 3.782 0.0005* 
Fluency at baseline 0.381 0.134 0.164 8.070 2.841 0.0007* 
Long-term memory at 
baseline 
0.250 0.118 0.088 4.476 2.116 0.0415* 
Working memory at 
baseline 
0.3177 0.104 0.185 9.195 3.032 0.0045* 
Visusal-spatial functions at 
baseline 
0.3122 0.106 0.173 8.543 2.923 0.0060* 
Delta at baseline -0.379 1.413 -0.026 0.072 -0.268 0.7900 
Theta at baseline -3.289 0.900 0.255 13.360 -3.655 0.0008* 
Alpha1 at baseline 1.434 1.296 0.006 1.225 1.107 0.2759 
Alpha2 at baseline 3.247 1.650 0.073 3.871 1.968 0.0470* 
Beta at baseline 3.364 1.553 0.093 4.692 2.166 0.0372* 
Median frequency at 
baseline 
0.387 0.148 0.138 6.791 2.606 0.0133* 
 
Table 12.2. Multivariate regression model with significant cognitive predictors (domains: 
attention, executive functions, and fluency), selected in univariate models. CI-OCS was 
introduced as dependent variable. 
Residual standard error: 0.5622, F-statistic: 6.332 on 3 and 33 DF, Adjusted R-squared:  0.3033, p-
value: 0.001638.  
Proportion of variance explained by model: 36.52%, metrics are not normalized. 
Predictor Estimate Standard 
error 
 
t value p-value Variance 
importance 
metrics, % 
Attention at baseline 0.129 0.138 0.932   0.3583 7.36 
Executive functions at 
baseline 
0.427 
 
0.159 
 
2.684 
 
0.0113* 
 
20.01 
 
Fluency at baseline  0.167 
 
0.149 
 
1.119 
 
0.271 
 
9.15 
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Table 12.3. Multivariate regression model with significant cognitive predictors (domains: 
long-term memory, working memory, and visual-spatial functions), selected in univariate 
models . CI-OCS was introduced as dependent variable. 
Residual standard error: 0.5715, F-statistic: 5.768 on 3 and 33 DF, Adjusted R-squared:  0.2844, p-
value: 0.002755 
Proportion of variance explained by model: 34.38%, metrics are not normalized. 
Predictor Estimate Standard 
error 
 
t value p-value Variance 
importance 
metrics, % 
Long-term memory at 
baseline  
0.150 
 
0.110 
 
1.357 
 
0.1840 
 
6.96 
 
Working memory at 
baseline 
0.236 0.103 2.276 0.0295* 15.01 
Visusal-spatial functions at 
baseline 
0.193 0.108 1.778 0.0845 12.41 
 
Table 12.4. Multivariate regression model with significant qEEG spectral predictors, 
selected in univariate models . CI-OCS was introduced as dependent variable. 
Residual standard error: 0.5928, F-statistic: 3.688 on 4 and 32 DF, Adjusted R-squared:  0.2300, p-
value: 0.01404 
Proportion of variance explained by model: 31.52%, metrics are not normalized. 
Predictor Estimate Standard 
error 
 
t value p-value Variance 
importance 
metrics, % 
Theta at baseline -5.267 2.084 -2.527 0.0167* 17.67 
Alpha2 at baseline -4.4759  3.976  -1.126  0.2687  4.16 
 
Beta at baseline -2.034  2.398  -0.848  0.4026  4.05 
 
Median frequency at 
baseline 
0.195  0.435 0.449  0.6568  5.64 
 
 
Explained variance of the overall model was 66.9%, of which “executive functions” 
made 27.5%, GRMP theta – 25.8%, and “working memory” – 13.6% (Table 13).  
Table 13. Multivariate regression model with significant qEEG spectral and cognitive 
predictors. CI-OCS was introduced as dependent variable. 
Residual standard error: 0.4057, F-statistic: 22.280 on 3 and 33 DF, Adjusted R-squared:  0.6394, p-
value: 4.542e-08 
Proportion of variance explained by model: 66.92%, metrics are not normalized. 
Predictor Estimate Standard 
error 
 
t value p-value Variance 
importance 
metrics, % 
Theta at baseline -3.157 0.641 -4.920 2.33e-05 
* 
25.79 
Executive functions at 
baseline 
0.544 0.106 5.127 1.27e-05 
* 
27.52 
 
Working memory at 
baseline 
0.187  0.072 2.588 0.0142 * 13.61 
 52 
 
V. V. Cozac (Kozak) 2018 
 
Additionally, we checked if age, sex, and education had confounding effect on each of 
the three significant variables (GRMP theta, “executive functions,” and “working 
memory”). No confounding effects were identified (Figure 8). 
Figure 8. Results of the linear regression analyses.  
Confounding effect of age, male sex, and education on the significant predictors of cognitive decline (GMRP 
theta, executive functions, and working memory). The variance of the models, that is explained by these 
predictors, is shown. 
 
 
 
ROC-Curve Analyses 
Receiver operating characteristic were built using variables: GRMP theta, “executive 
functions,” and “working memory.” Best accuracy was identified in GRMP theta: AUC = 
75%, specificity = 63%, specificity = 77% (Figure 9). 
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Figure 9. Receiver operating characteristic (ROC)-curves analyses. 
 
Coordinates GMRP theta Executive  
functions 
Working  
memory 
Area under the curve 0.746 0.719 0.655 
Specificity 0.631 0.684 0.736 
Sensitivity 0.777 0.722 0.555 
Positive predictive value 0.666 0.684 0.666 
Negative predictive value 0.750 0.722 0.636 
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Random Forest 
Global relative median power theta was classified as the most important variable (MDA 
= 7.49, MDGC = 1.63) (Table 14). 
Table 14. Random Forest analysis.  
Type of random forest: regression 
Number of trees: 1000 
No. of variables tried at each split: 1 
Mean of squared residuals: 0.2796442, % Var explained: 37.03 
Predictors Mean Decrease Accuracy Mean Decrease Gini Coefficient 
Theta at baseline 7.49 1.63 
Alpha2 at baseline 4.28 1.20 
Beta at baseline 4.98 1.29 
Median frequency at baseline 1.79 1.27 
Attention at baseline 2.91 1.40 
Executive functions at baseline 7.29 1.67 
Fluency at baseline 4.39 1.51 
Working memory at baseline 3.69 1.51 
Long-term memory at baseline 1.38 1.25 
Visual-spatial functions at baseline 4.58 1.43 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 55 
 
V. V. Cozac (Kozak) 2018 
Chapter 6. Effects of deep brain stimulation in Parkinson’s disease on 
psychiatric parameters with regard to age of the patients (clinical 
study) 
 
Deep brain stimulation is widely used as neurosurgical treatment in PD, because it 
improves the motor manifestations of PD and reduces the need for antiparkinsonian 
medication (Fasano and Lozano, 2015).  The intraoperative, short-term, and long-term 
adverse effects of DBS in PD are well known (Falowski et al., 2015). However, when 
candidates for DBS are appropriately selected, the benefit of the procedure in terms of an 
improved quality of life generally justifies its small risk. Moreover, it was concluded in the 
EARLYSTIM study (Schuepbach et al., 2013) that STN-DBS yielded a better outcome than 
drug treatment alone in patients with early (rather than advanced) motor complications 
of PD. In that study, the incidence of serious adverse events (SAE) was compared in 
patients in the medical versus the surgical arms of the study. The mean age of the 124 
patients who underwent surgery was 52.9 years, and they were followed up for two years. 
Today, no consensus exists regarding an age cut-off  for DBS as a treatment of PD (Vesper 
et al., 2007; Floden et al., 2014). In the present study, we retrospectively determined the 
incidences of SAE after STN-DBS in a group of patients whose mean age was 63.2 years 
and compared it to the incidence of SAE among the patients in the EARLYSTIM study.  
Methods 
Patients selection 
We retrospectively analyzed the medical records of PD patients who underwent STN-
DBS in our institution, which were extracted from the clinical and research databases of 
the University Hospital Basel. The study protocol was approved by the local ethics 
committee (Ethikkommission beider Basel). The records were analyzed for a period of 
two years after STN-DBS. The inclusion and exclusion criteria from the EARLYSTIM study 
(Schuepbach et al., 2013) were used to select cases for the analysis, with the exception of 
age: in the present study we focused on a group of relatively old operated patients (see 
Panel 4 for the criteria of selection). The age of the patients in the EARLYSTIM study 
ranged from 18 to 60 years, in the group of patients from our database, the age ranged 
from 58 to 70 years. 
Panel 4. Selection criteria for the cases 
The major inclusion criteria were adjusted to those, used in the EARLYSTIM study: 
- diagnosis of idiopathic Parkinson’s disease with a duration of at least four years before STN-DBS;  
- STN-DBS was performed before 1 July 2013;  
- moderate disease severity (i.e. Hoehn and Yahr score less than 3 in the “ON” medication state, 
assessed within 14 days before the STN-DBS). 
The exclusion criteria were:   
- dementia according to DSM-IV; 
- a score of 25 or higher on the BDI-II; 
- any psychotic disorder according to DSM-IV criteria. 
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Twenty six patients with PD (11 women, 15 men) who underwent STN-DBS in the 
period from January 1, 2008 to June 30, 2013, were selected for the analysis (i.e. the 
“BASEL group” of patients in what follows, as opposed to the “EARLYSTIM group”). 
Operative procedure for STN-DBS 
In each patient, Medtronic 3389 electrodes were stereotactically implanted into the 
STN bilaterally under local anesthesia with the aid of intraoperative microelectrode 
recording and test stimulation, after coordinate- and visually-based target selection and 
trajectory calculation with the aid of preoperative computed tomography and magnetic 
resonance scans. The pulse generator was implanted subsequently under general 
anesthesia. 
Analyses of the cases 
Patients with PD who were scheduled for DBS underwent interdisciplinary assessment 
(including detailed neurological and neuropsychological examinations) before and, in 
general, every 6 months after the procedure. The results of these assessments were stored 
in the hospital’s clinical and research databases and were compiled for this analysis. 
Whenever a patient needed his/her family doctor’s assistance for problems potentially 
related to Parkinson’s disease or to DBS, but was not admitted to the hospital for these 
problems, the family doctor reported such cases to the clinical and research database. The 
interdisciplinary assessment performed within the 14 days before the STN-DBS will be 
referred to as the “baseline assessment,” while that performed 24 months later will be 
referred to as the “2-year assessment.”  
The following variables were analyzed: subscales II and III of the UPDRS, the Brief 
Psychiatric Rating Scale (BPRS), BDI II, and LED. In some cases, diagnoses made by other 
medical specialists (e.g., cardiologist) were used in addition as an indication of the 
patient’s general medical condition. 
SAE were defined according to the Medical Dictionary for Regulatory Activities, version 
14.1, as any registered events that led to death, disability, or prolonged or new 
hospitalization with serious health impairment. The list of SAE was adjusted to the list of 
SAE described in the EARLYSTIM study. Thus, the SAE were grouped in the following 
categories: 1) suicide, 2) life-threatening events, 3) events related to medication or 
stimulation, 4) events related to surgery or device, 5) events related to PD. We calculated 
the number of reported SAE in each category for each patient within the 24 months after 
STN-DBS. 
Statistical analysis 
Statistical calculations were done with the R version 3.1.2 open source software. 
Baseline mean and standard deviations of the demographic and clinical parameters of the 
groups were compared with an unpaired Student’s t-test. The numbers of patients with 
SAE were compared with the chi-squared test with Yates correction to prevent 
overestimation of statistical significance for small data; significance was set at p < 0.05. 
Linear regression models were applied to adjust for potential confounders in statistically 
significant differences. 
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Results 
The results of comparison of the demographic and clinical features of the two groups 
are shown in Table 15. The patients in BASEL group were older than the patients in the 
EARLYSTIM study who underwent surgery (mean difference 10.3 years, 95% confidence 
interval (CI) 7.7 to 12.9). Disease duration in the BASEL group was longer (mean 
difference 2.7 years, CI: 1.3 to 4.1).  
The results of the comparison of SAE incidence between the two groups are shown in 
Table 16. Significant differences in the incidence of SAE were found in the category “Event 
related to medication or stimulation” (Chi-squared=4.5, p=0.03) and in its subcategory 
“psychosis and hallucinations” (Chi-squared=24.7, p<0.01). The characteristics of 
psychosis and hallucination of the patients in the BASEL group are shown in Table 17.  
Regression models showed no influence of clinical and demographic parameters on the 
incidence of psychosis. 
 
Table 16. Serious adverse events. 
*Worsening of mobility was defined as tremor, rigidity, akinesia, wearing off of medication effect, 
dystonia, or worsening of symptoms of PD. 
**Dislocation of device was defined as dislocation of the stimulator, cable, or lead. 
***Reoperation was necessary in order to repair the stimulator or lead. 
Parameters EARLYSTIM STN-DBS2 
(n = 124) 
BASEL group 
(n=26) 
Chi-square 
test, p value 
Event no. of 
events 
no. of 
patients 
(%) 
no. of 
events 
no. of 
patients 
(%) 
 
Total serious adverse events 123 68 (54.8) 61 18 (69.2) ns 
1.Death, all by suicide 2  2 (1.6)  0 0 ns 
2.Life-threatening event 14  12 (9.7)  2 2 (7.7) ns 
3.Event related to 
medication or 
stimulation 
24  24 (19.4) 10 10 (38.5) 0.03 
Worsening of 
mobility* 
5  5 (4.0)  1 1 (3.8) ns 
Motor fluctuations 0 0 1 1 (3.8) ns 
Table 15.  Demographic and clinical features of the groups at baseline.   
LEDD – levodopa equivalent daily dose; BPRS – Brief Psychiatric Rating Scale; BDI II – Beck Depression 
Inventory II; UPDRS –Unified Parkinson Disease Rating Scale. 
Variable EARLYSTIM STN-DBS BASEL group t-test 
No of subjects 124 26 - 
Males (%) 94 (75.8) 15 (57.7) ns 
Age (mean ±SD) 52.9 ±6.6 63.2 ±3.3 p<0.01 
Duration of PD (mean ±SD) 7.3 ±3.1 10.0 ±3.7 p<0.01 
LED (mean ±SD) 918.8 ±412.5 962.0 ±562.6 ns 
BPRS score (mean ±SD) 25.3 ±1.0 24.8 ±5.1 ns 
BDI-II score (mean ±SD) 
“ON” medication state 
10.1 ±0.6 9.5 ±4.0 ns 
UPDRS-II (mean ±SD) 15.0 ±0.8 15.4 ±5.8 ns 
UPDRS-III (mean ±SD) 33.2 ±1.8 34.8 ±12.5 ns 
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Dyskinesia 1 1 (0.8) 0 0 ns 
Psychosis or 
hallucinations 
0 0 5 5 (19.2) <0.01 
Anxiety 0 0 0 0 - 
Impulse control 
disorder 
1  1 (0.8)  0 0 ns 
Depression 6  6 (4.8)  2 2 (7.7) ns 
Suicidal ideation 1  1 (0.8)  0 0 ns 
Suicidal attempt 2  2 (1.6) 0 0 ns 
Cardiac disorder 0 0 0 0 - 
Injury 3  3 (2.4)  0 0 ns 
Respiratory or 
thoracic disorder 
1  1 (0.8)  0 0 ns 
Other 4  4 (3.2) 0 0 ns 
4.Event related to 
surgery or device 
26  22 (17.7) 8 8 (30.8) ns 
Impaired wound 
healing 
4 4 (3.2) 2 2 (7.7) ns 
Intracerebral abscess 
or edema 
2  2 (1.6) 2 2 (7.7) ns 
Dislocation of device** 5 4 (3.2) 1 1 (3.8) ns 
Reoperation 
necessary*** 
4 2 (1.6) 2 2 (7.7) ns 
Other 11 10 (8.1) 1 1 (3.8) ns 
5.Event related to PD 57 39 (31.5) 41 10 (38.5) ns 
 
Table 17. Patients with serious psychosis and hallucinations. 
No Age 
(years) 
Sex Clinical presentation Time of 
manifest after 
STN-DBS 
Result 
1 60 female Visual illusions, sense of presence, 
fear  
8 weeks  New hospitalization 
2 62 female Delusion of spousal infidelity, 
suspicions of harmful thoughts 
8 weeks New hospitalization 
3 60 male Passage hallucinations, delusion 16 weeks New hospitalization 
4 69 male Paranoia with aggression 10 days  Prolonged 
hospitalization 
5 63 female Visual illusions, sense of presence, 
fear 
12 weeks New hospitalization 
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Chapter 7. Effects of deep brain stimulation in Parkinson’s disease on 
cognitive parameters with regard to age of the patients (clinical study) 
Introduction 
DBS alleviates motor symptoms of PD and allows patients to reduce their levodopa 
dose, thereby lessening side effects. DBS also improves patients’ quality of life, especially 
if they have reached the plateau of oral medication (Deuschl et a., 2006). According to 
some reports, DBS is even superior to medical therapy in patients with PD and early motor 
complications (Schuepbach et al., 2013). DBS is not considered to cause major cognitive 
side effects, but some research groups have reported that it causes a decline in verbal 
fluency (VF) (Saez-Zea et al., 2012). The mechanism of the DBS-induced decline in VF is 
unclear (Ehlen et al., 2014). Some researchers suggest that it may be due to a “microlesion” 
of the brain tissue, produced by the passage of the electrodes during implantation 
(Maltete et al., 2008). Worsening fluency was associated with lower perfusion in the left 
dorsolateral prefrontal cortex, the anterior portion of the cingulate cortex, and the ventral 
portion of the caudate nucleus (Cilia et al., 2007). Other authors have suggested that the 
decline in VF may be directly due to the DBS procedure, but is rather related to the age of 
the patient (Smith et al., 2014). In this study, we investigated the possible impact of 
patients’ age, level of education, disease duration, LED, disease progression (Hoehn & 
Yahr score, UPDRS- III), cognition (MMSE), and BDI-II on VF performance as outcome 
parameter, measured by a neuropsychological test battery after DBS in PD patients. We 
attempted to determine whether the decline in VF is caused by DBS itself or it, instead, 
reflects an influence of other factors. 
Methods 
Patients selection 
Fourty three patients referred to the interdisciplinary team for functional stereotaxy 
at the Hospital of the University of Basel, Switzerland, were consecutively and 
prospectively included in the study from 2008 to 2014 (see Panel 5). The selection criteria 
were: clinically diagnosed idiopathic PD, no dementia or major ongoing psychiatric illness 
(according to DSM-IV), and adequate German language skills. The clinical diagnoses of 
idiopathic PD (Hughes et al., 1992) and assessments of disease severity were made by an 
experienced neurologist. The neurologist had no access to the patients’ 
neuropsychological data. Twenty one patients who underwent STN-DBS were compared 
to 22 patients who did not undergo DBS. The study protocol was approved by the local 
ethics committee (Ethikkommission beider Basel, ref. No: 135/11). All patients provided 
their written informed consent. The characteristics of the two groups at baseline are 
shown in Table 18. Both groups underwent regular clinical follow-up and neurocognitive 
assessment. 
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Panel 5. Flow chart  
 
 
Neuropsychological and neuropsychiatric assessment 
All of the patients underwent cognitive evaluation by a neuropsychologist and a 
psychiatric evaluation by a psychiatrist. The MMSE was used as a screening tool for 
dementia. 
Table 18.  Characteristics of the patient groups at baseline. 
Medians and ranges are shown. * - chi-squared test for sex distribution in the two groups was used; ** - five 
missing; *** - four missing; ns = non-significant. 
Parameters Non-DBS  DBS-STN Mann-
Whitney U-
test 
Number of patients 22 21 - 
Age (years) 65.0 [46-77] 63.0 [49-74] ns 
Disease duration (years) 8.0 [4-22] 11.0 [4-18] ns 
Highest educational level (years) 14.0 [9-20] 14.0 [5-20] ns 
Sex (% male) 0.68 0.60 ns* 
Levodopa equivalent dose (mg) 678 [100-4687] 960 [180-2342] ns 
Mini Mental State Examination  28.5 [27-30] 29 [27-30]  ns 
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The cognitive evaluation was performed with a battery of neuropsychological tests 
(Lezak, 1995), which were grouped in cognitive domains as suggested in Zimmermann et 
al. (2015). Semantic and phonemic categories of VF were analyzed as outcome parameter. 
The cognitive performance of all subjects was analyzed at baseline – immediately before 
surgery in the STN-DBS group, and on enrollment in the study in the non DBS group – both 
at baseline and after a variable period ranging from 4 to 10 months. The median time of 
follow up in both groups was 7 months. To make the follow-up periods comparable, we 
used a reliable change index, as described by Frerichs and Tuokko (2006). 
Statistical analyses 
Statistical calculations were done with the R version 3.1.2 free software. Sample 
parameters at baseline were evaluated after normalization, with two-tailed t-test. Chi-
square tests were used to compare the sex distribution of the two groups. The cognitive 
test findings were subjected to the population-based standardization process described 
by Berres et al. (2000) with adjusted covariates including age, sex and educational level. 
Cognitive performance scores were compared with two-tailed t-test with confidence 
intervals and Bonferroni correction for multiple testing. The results are given as means 
and standard deviations and as medians and interquartile ranges. Linear regression 
model with stepwise backwards elimination was used to control for significant 
confounding effect on VF performance within and across the groups of patients; p < 0.05 
was considered as statistically significant. 
Results 
Analysis of changes in cognitive performance over time by t-test. The patients’ 
cognitive performance is shown in Table 19. After multiple corrections a significant 
decline was found only in the semantic category of VF in the STN-DBS group. The analyses 
using stepwise backward linear regression model was performed in pooled sample and 
across groups with VF performance as dependent variable. In the pooled sample 
significant effects of surgery, age, and combined age x surgery were detected. In the STN-
DBS sample significant effects of age and disease duration were detected. In the non-
operated sample none of the investigated parameters had significant confounding effect 
(Table 20).  
 
 
 
 
 
Hoehn & Yahr scale 2 [1.5-3] 2 [1.5-3] ns 
UPDRS-III 16.5 [0-37] 18 [0-52] ns 
Beck depression inventory-II 7.0** [0-15] 6.8*** [1-18] ns 
Follow-up evaluation (months) 7 [4 – 10] 7 [4.5 – 10] ns 
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Table 19. Cognitive tests at baseline and follow-up and cognitive change scores. 
A positive change score means that cognitive performance improved, and a negative one means that it 
worsened. Negative mean differences in change score indicate poorer performance of the STN-DBS group. 
Part 1.  
 
Cognitive tests Baseline Follow-up 
STN-DBS 
median [range] 
Non-DBS 
median [range] 
p-value 
t-test 
STN-DBS 
median 
[range] 
Non-DBS 
median [range] 
Semantic 
category of 
verbal fluency 
-0.40 [-3.5; 1.7] -0.67 [-3.5; 0.9] 0.38 -1.24 [-2.9; 
0.8] 
-0.33 [-3.7; 2.3] 
Phonemic 
category of  
verbal fluency 
-0.10 [-4.1; 2.0] -0.08 [-2.9; 2.0] 0.38 -0.67 [-5.0; 
0.6] 
-0.32 [-1.5; 2.5] 
California verbal 
learning test 
-0.50 [-3.0; 1.0] -0.76 [-2.4; 0.7] 0.49 -0.10 [-2.8; 
1.2] 
0.33 [-3.0; 3.7] 
Trail making A 0.00 [-2.1; 2.6] -0.20 [-2.6; 1.9] 0.14 0.00 [-2.1; 2.2] -0.15 [-3.4; 2.5] 
Digit span 
backward 
-0.36 [-1.7; 2.3] -0.04 [-2.7; 2.3] 0.76 -0.36 [-2.3; 
1.0] 
0.04 [-1.7; 2.6] 
Boston naming 
test 
-0.30 [-4.8; 1.4] -0.27 [-1.4; 1.0] 0.33 -0.24 [-2.9; 
1.3] 
-0.22 [-2.1; 1.2] 
Rey-Osterrieth 
complex figure 
test 
-0.30 [-2.1; 2.3] -0.21 [-2.5; 1.4] 1.00 -0.25 [-3.3; 
2.2] 
0.10 [-2.8; 1.7] 
Part 2. 
 
Cognitive tests Change Score 
STN-DBS 
mean (standard 
deviation ) 
Non-DBS 
mean 
(standard 
deviation) 
Mean 
difference 
p-value 
corrected 
Cohen’s d 
 
Semantic 
category of 
verbal fluency 
-0.64 (1.14) 0.35 (0.90) -0.99 <0.01 0.94 
Phonemic 
category of  
verbal fluency 
 
-0.52 (0.79) 0.09 (0.82) -0.61 0.10 0.74 
California verbal 
learning test 
0.43 (1.28) 0.88 (1.12) -0.45 0.41 0.46 
Trail making A -0.17 (0.81) 0.23 (0.75) -0.40 0.81 0.51 
Digit span 
backward 
-0.20 (0.78) 0.18 (0.72) -0.38 0.54 0.51 
Boston naming 
test 
-0.06 (1.15) -0.01 (1.00) -0.05 1.0 0.01 
Rey-Osterrieth 
complex figure 
test 
-0.06 (0.59) -0.06 (0.96) 0 1.0 0.01 
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Table 20. 
The results of the regression analyses predicting semantic fluency performance by potentially confounding 
factors are presented. Each row represents a linear regression model analysis predicting the variable in the 
first column. Columns 2 - 10 show estimates of the predictors with confidence intervals in parenthesis. The last 
column shows the overall model parameters. NA- not significant. 
 
Semanti
c verbal 
fluency 
score in: 
DBS 
surger
y 
Age x 
DBS 
surgery  
Age 
(years) 
Male 
sex 
Educa
tional 
level 
(year
s) 
Disease 
duratio
n 
(years) 
Hoeh
n and 
Yahr 
score 
MMS
E 
score 
UPDR
S III 
score 
BDI-
II 
scor
e 
Model 
- pooled 
sample 
(n=43) 
ns -0.34 
(-0.09 to 
0.10) 
p=0.003 
ns ns ns ns ns ns ns ns Adjuste
d 
R2=0.34; 
p<0.001 
- STN-
DBS 
(n=21) 
- ns -0.08 
(-0.11 to 
-0.004) 
p=0.006 
ns ns -0.19  
(-0.02 to 
-0.22) 
p=0.003 
ns ns ns ns Adjuste
d 
R2=0.49; 
p=0.004 
- Non 
DBS 
(n=22) 
- ns ns ns ns ns ns ns ns ns ns 
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Chapter 8. Olfactory deficits and quantitative EEG in patients with 
Parkinson’s disease (clinical study) 
 
The decline of olfaction is a feature of an early stage of PD, which may be useful as a 
premotor biomarker in PD (Haehner et al., 2007; Chaudhuri and Odin 2010; Haas et al., 
2012; Berg et al., 2013), it is correlated with decrease hippocampal activity (Welge-Lüssen 
et al., 2009) and predicts brain atrophy (Wattendorf et al., 2009). In a recently suggested 
classification of the non-motor subtypes of PD, «Park weight subtype» concludes 
phenotypes with olfactory impairment and risk of dyskinesia (Sauerbier et al., 2016b). In 
addition, the olfactory decline may be helpful in differential diagnosis of PD (Doty 2012). 
Hyposmia has a high diagnostic accuracy, in comparison to other neurodegenerations; in 
PD the olfactory disturbance is much more severe (Katzenschlager and Lees 2004; Silveira-
Moriyama et al., 2009; Krismer et al., 2017). The olfactory decline in PD also positively 
correlates with specific cognitive domains, such as executive function and episodic verbal 
memory (Bohnen et al., 2010; Damholdt et al., 2011; Parrao et al., 2012). Moreover, 
olfaction testing with University of Pennsylvania Smell Identification Test predicted 
cognitive decline after three years (Fullard et al., 2016). Cognitive decline in PD is 
associated with slowing of EEG, and this slowing can be identified with quantitative 
analysis of the EEG (Caviness et al., 2007; Babiloni et al., 2011; Klassen et al., 2011). 
Thus, we assumed, that olfactory function in PD could correlate with cognitive 
performance and EEG parameters; and the combination of smell identification testing, 
cognitive assessment and EEG may increase the precision of PD identification and become 
a marker of higher risk of cognitive decline in PD patients. In this study, we aimed to 
compare olfactory function between PD patients and healthy controls to analyse 
correlations between the olfaction capacity, clinical features and EEG. 
Methods 
Patients selection 
We performed a cross-sectional retrospective analysis of two samples of participants: 
PD patients and healthy controls. These participants were selected from a study database 
from the Hospital of the University of Basel, Switzerland according to the availability of 
the results of smell identification testing. The respective study is an ongoing observational 
cohort investigation, focused on the EEG and genetic markers of cognitive outcomes in 
PD; the details of this study are provided elsewhere (Cozac et al., 2016). The PD sample 
comprised 54 patients (median age 68 years, males 69%), and the HC sample comprised 
21 participants (median age 67 years, males 67%). In both samples, we analysed the 
following baseline tools: Mini-Mental State Examination (MMSE), 5 neuropsychological 
tests, EEG, and olfactory «Screening 12 Test» («Sniffin’ Sticks», commercially available, 
Burghart Messtechnik GmbH, Wedel, Germany). Only the PD sample was assessed with 
UPDRS. LED was calculated for all PD patients (Tomlinson et al., 2010). All participants 
provided written informed consent to the processing of personal data within the study, 
which was approved by the local ethics committee (Ethikkommision beider Basel, letters 
No 135/11 and 294/13).  
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Assessment of the olfactory function 
The olfactory function was assessed using the «Sniffin Sticks Screening 12 Test» which 
consists of 12 felt-tip pens filled with an odorant, e.g. orange, coffee, fish (Kobal et al., 
1996). Removal of the cap releases the odour. The type of the odorant is coded and is not 
known to the examinee.  The pen is held approximately two centimetres in front of the 
examinee’s nostrils, and the examinee receives a verbal command to inhale the odour 
with both nostrils for two seconds. Then the examinee is given a card with 4 variants of 
odour (including the correct one), and – in a forced choice paradigm - is asked to select 
the correct odour. The number of correctly identified odorants is summed up to calculate 
the «Sniffing score» (SnSc) ranging from 0 to 12. 
EEG processing    
We recorded continuous EEG with 214 active electrodes in each participant, in a 
relaxed eyes-closed state. The electrode located at CZ was used as a reference (Net Station 
300; Electrical Geodesics, Inc). All recordings were processed with “TAPEEG” toolbox 
(Hatz et al., 2015). The sampling rate was set at 1000 Hz, oscillations were filtered with 
2500 order least-square filter with band-pass 0.5 – 70 Hz, and notch 50 Hz. Detection and 
removal of artefacts (e.g. eye blinks) were fully automated, by an independent component 
analysis. Channels with bad activations were automatically detected and interpolated by 
spherical spline method. Global relative median power (GRMP) was calculated in 
frequency ranges: theta (4 – 8 Hz) and alpha (8 – 13 Hz). Alpha/theta ratio (ATR) was 
subsequently calculated. In other words, ATR is an indicator of EEG slowing, the smaller 
the ratio, the slower the EEG. 
Cognitive tests 
We used the following 5 tests: Wisconsin Card Sorting Test: correct categories (WCST), 
Trail Making Test time for part A (TMTA), Test of Attentional Performance – Working 
Memory (2-back task): omissions (TAPWMO), Semantic verbal fluency test: correct 
answers (SVFC), and Phonemic verbal fluency: correct answers (PVFC). Test variables 
were normalized with reference to a normative database of 604 healthy controls from the 
Memory Clinic, Felix Platter Hospital of Basel, Switzerland (Berres et al., 2000). 
Statistics 
Statistical calculations were performed with R tool for statistical calculations (R Core 
Team 2015). We used corrected Wilcoxon and chi-squared tests to compare variables 
between the samples. Spearman rank correlation test was applied to check the relation of 
SnSc with the following parameters: age, sex, disease duration (since the first diagnosis), 
years of education, MMSE, LED, ATR, UPDRS-III, WCST, TMTA, TAPWMO, SVFC, and PVFC. 
We applied receiver operating ROC-curves to analyse the classification value of the 
following variables: SnSc, ATR and a combined score (SnSc+ ATR). For ROC-curve 
analyses, PD and HC samples were merged, and the presence of PD was used as an 
outcome. Bonferroni correction for multiple testing was applied. The level of statistical 
significance was set at .05. 
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Results 
The samples are shown in Table 21. In comparison to HC, in PD patients the following 
parameters were significantly decreased: SnSc, WCST, TMT-A, and SVFT; and ATR was 
significantly decreased. 
Table 21. Comparison of the PD-sample with HC-sample.  
Comparison of the PD-sample with HC-sample. For continuous parameters Wilcoxon test  with Bonferroni 
correction was applied; number of males was compared with Chi-squared test; ns = p>.05 
Parameter PD, n=54 HC, n=21 p value (95% conf.int.) 
males, n (%) 37 (69) 14 (67) ns 
age, years 68 [45, 85] 67 [57, 78] ns 
years of education 15 [9, 20] 15 [10, 20] ns 
MMSE 29 [24, 30] 30 [26, 30] ns 
disease duration, 
years 
3.41 [1, 23] - - 
UPDRS-III 18 [1, 47] - - 
LED, mg/day  475 [0, 2950] - - 
SnSc  5.5 [2, 12] 10 [7, 12] p<.001 (-5.0, -2.0) 
WCST -0.54 [-2.13, 3.23] 0.05 [-1.33, 2.17] p<.05 (-0.9, -0.1) 
SVFC -0.30 [-2.08, 1.94] 0.11 [-1.42, 2.89] p<.05 (-1.2, -0.1) 
PVFC 0.22 [-1.95, 2.56] 0.22 [-1.72, 1.96] ns 
TMTA -0.44 [-3.09, 2.27] 0.57 [-1.11, 3.34] p<.01 (-1.5, -0.3) 
TAPWMO 0.25 [-2.33, 2.80] -0.10 [-2.33, 2.32] ns 
ATR 1.32 [0.24, 5.39] 1.96 [0.79, 7.71] p<.05 (-1.0, -0.01) 
 
In PD sample, SnSc correlated with age, disease duration, UPDRS-III, and the following 
items of UPDRS-III: “Postural stability” (rho=-0.43, p<.01), “Leg agility, right” (rho=-0.43, 
p<.01), “Gait” (rho=-0.29, p<.05), and “Rigidity neck” (rho=-0.30, p<.05) (Tables 22 and 
23). In HC sample, SnSc correlated with age only (rho=-0.62, p<.05). No correlation of SnSc 
with ATR was identified in both samples.  
Table 22. Correlation of SnSc with samples’ characteristics. 
* - p<.05; ** - p<.01; *** - p<.001  
Parameter Rho (PD sample) Rho (HC sample) 
male sex -0.05 -0.29 
age, years -0.70*** -0.42** 
years of education 0.23 0.21 
MMSE 0.30 0.30 
disease duration, years -0.49*** - 
UPDRS-III -0.70** - 
LED, mg/day  -0.24 - 
WCST 0.02  0.08  
SVFC -0.03  -0.08 
PVFC -0.20 -0.12 
TMTA 0.25  -0.10 
TAPWMO 0.25  0.10  
ATR 0.23 0.20 
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Table 23. Correlation of SnSc with items of UPDRS-III in PD sample.  
* - p<.05; ** - p<.01; *** - p<.001 
Items  Rho  
speech -0.15 
facial expression -0.23 
tremor at rest: face -0.14 
tremor at rest: right upper extremity -0.12 
tremor at rest: left upper extremity -0.05 
tremor at rest: right lower extremity -0.05 
tremor at rest: left lower extremity -0.01 
action or postural tremor of hands: right -0.08  
action or postural tremor of hands: left -0.22  
rigidity: neck -0.30* 
rigidity: right upper extremity -0.20  
rigidity: left upper extremity -0.19  
rigidity: right lower extremity -0.24 
rigidity: left lower extremity -0.24 
finger taps: right -0.05 
finger taps: left -0.10 
hand movements: right -0.12 
hand movements: left -0.12 
rapid alternating movement of hands: right -0.08 
rapid alternating movement of hands: left -0.24 
leg agility: right -0.43*** 
leg agility: left -0.24 
arising from chair -0.12 
posture -0.25 
gait -0.29** 
postural stability -0.43*** 
body bradykinesia and hypokinesia -0.23 
 
The highest AUC was found in the combined marker (SnSc+ ATR): 86.5%, specificity 
100%, sensitivity 64.8%); followed by SnSc (AUC 86.1%, spec. 95.2%, sens. 66.7%), and 
α/θ (65.0%, spec. 61.9%, sens. 70.3%), Fig. 10. 
 
 
 
 
 
Figure 10. ROC-curves analyses. 
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Chapter 9. Integrated discussions and conclusions 
 
PD is a multifactorial neurodegenerative disorder featuring a range of motor and non-
motor symptoms. PD comprises progressive cognitive and neuropsychiatric symptoms, 
which eventually result in PD-D. A number of factors may influence the risk of cognitive 
decline in PD, including genetic, neurophysiological, and psychosocial factors. The focus 
of this thesis was on contributing to the research on genetics and qEEG as the risk factors 
of PD-D. In addition, a number of clinical factors were also considered (DBS and olfaction), 
as these may be related with the risk of cognitive decline in PD. 
Discussions 
The discussions of the studies perfomed within this research are listed below. 
In the study I, the results of our review support the idea that spectral and 
connectivity markers have a significant impact in discriminating PD patients with 
different level of cognitive decline, regardless the variety of approaches to calculate 
these markers. To summarize, a slowing of EEG frequencies correlates with a decline of 
cognition. Accordingly, an increase of spectral powers in the “slow” frequency bands < 8 
Hz (delta and theta), and a decrease in the “fast” frequency bands > 8 Hz (alpha, beta and, 
less significantly, gamma), are spectral markers of PD-related cognitive decline. 
Topographically, occipital, parietal and temporal regions show the higher significance.  
Additionally, the above mentioned spectral markers showed significant hazard ratio in 
predicting conversion of non-demented PD patients to PD-D. Patients with spectral 
powers in “fast” waves below, and in “slow” waves above the median values, have 
significantly higher risk of developing PD-D within two to seven years.  
The connectivity patterns of the PD patients with cognitive impairment show changes 
in the same frequency ranges, where spectral markers of cognitive decline are identified: 
mostly in theta (4-8 Hz), alpha1 (8-10 Hz) and beta (13-30 Hz) ranges. The 
connectivity patterns of PD patients with cognitive decline changed in frontal, temporal, 
parietal and occipital regions. However, the number of connectivity studies focusing on 
cognitive states of PD patients is still very small; by the same token the studies had 
different setting and various connectivity markers were investigated. A common trend of 
cognitive decline in PD seems to be a decrease of connectivity in parieto-temporo-
occipital regions. 
The qEEG potentially has high test-retest reliability, reflects cortical function, requires 
little cooperation, is non-invasive, easily to repeat, and avoids learning bias and restricted 
availability associated with some neuropsychological testing. In sum, qEEG markers could 
be a valuable aid for diagnosing and predicting PD-related cognitive decline. Furthermore, 
it may allow for timely selection of patients prone for pharmacological and non-
pharmacological interventions of prevention at a very early stage of PD and thereby 
potentially improve clinical results. Further studies with larger cohorts and longer 
periods of observation are expected. 
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In the study II, increase of GRMP theta (4–8 Hz), and decrease of cognitive 
performance in domains “executive functions” and “working memory” significantly 
predicted worse CI-OCS after three years.  
The findings in GRMP theta are in line with the data from cohort studies with semi-
automated processing of EEG (Klassen et al., 2011; Olde Dubbelink et al., 2014a). 
Additionally, in cross-sectional comparisons between Parkinson’s disease patients with 
dementia and matched healthy controls, spectral power in the frequency range below 8 
Hz was significantly increased in demented patients (Babiloni et al., 2011; Fonseca et al., 
2013). From a pathophysiologic perspective, EEG slowing in severe cognitive decline may 
be explained by disruption of thalamocortical circuits, and pathological synchronization 
of the brain motor systems with slow frequencies related to the sensory motor integration 
(Steriade et al., 1990; Rossini et al., 1991). We can speculate that these pathological 
changes precede clinical manifestation of cognitive decline in PD. With regard to cognitive 
factors, we found that worse scores in domains “executive functions” and “working 
memory” are significant predictors of cognitive decline. Zimmermann et al. (2015) in a 
cross-sectional analysis showed significant correlation of occipital median frequency with 
overall cognitive score, domains “executive functions,” “long-term memory,” “attention,” 
and “fluency” in dementia-free patients with PD. Olde Dubbelink et al. (2014a) found that 
fronto-executive (spatial span score) and posterior (pattern recognition memory) 
significantly predicted PD-D. Impairment of the executive functions is common in the 
early stage of PD (Kehagia et al., 2010). However, the cognitive profile of early stage PD is 
heterogeneous, and the significance of domain-specific cognitive deficits in identifying 
patients with a risk of dementia is still studied (Robbins and Cools, 2014). 
In the study III, we found a higher incidence of psychosis and hallucinations after 
STN-DBS in a sample of PD patients, who are about 10 years older, compared to the 
patients from the EARLYSTIM study.  
The effects of DBS on mental functioning are not clear, the pattern and expression of 
neuropsychiatric symptoms in operated patients with PD are highly variable (Volkmann 
et al., 2010). Some researchers have reported various types of psychiatric side-effects of 
DBS ranging from apathy and emotional lability to visual hallucinations, hypersexuality, 
and aggressive behavior (Soulas et al., 2008; Le Jeune et al., 2009; Bickel et al., 2010; Daniele 
et al., 2012; Qureshi et al., 2015). In a meta-analysis of 808 publications covering the time-
period 1996 – 2005 the most common psychiatric side-effect associated with DBS was 
delirium, making 4 to 8% of all psychiatric complications (Appleby et al., 2007). Most of 
psychiatric post-DBS side-effects are transient and treatable (Voon et al., 2006), however, 
in some case reports these side-effects manifested in a very severe form with long-term 
consequences (Zonana et al., 2011; Piccoli et al., 2015). Other researchers reported an 
improvement of psychiatric symptoms after DBS (Funkiewiez et al., 2004). Vesper et al. 
(2007) analyzed the outcomes of DBS in PD as a function of age, observing two groups of 
patients one year after surgery: those younger versus those older than 65 years. Frequent 
transient neuropsychiatric impairment was seen in both groups (the adverse events were 
not stratified with regard to severity). In another observational study by Shiina et al., 
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(2015) a sample of PD patients with mean age of 65 years was followed-up for 12 months 
after DBS. In that study, some of the patients experienced an improvement of pre-
operative psychiatric symptoms, some had psychiatric side-effects, and others had no 
changes in psychiatric state. Piasecki and Jefferson (2004) proposed three possible 
mechanisms of mental disturbance after DBS: effects of the electrode placement itself, 
neurotransmitter changes induced by stimulation, and worsening of a pre-existing mental 
disorder by DBS. There were described 3 regions in the STN, in which the neurons make 
part of the following functional circuits: sensorimotor (dorsolateral), motor 
(ventromedial) and limbic (medial) (Romanelli et al., 2004). Limbic circuits participate in 
emotional and behavioral control. The spread of electrical currents from the electrodes in 
STN after DBS may cause disturbances in limbic circuit, thus leading to psychiatric 
symptoms. Another theory explaining psychiatric complications after DBS is based on the 
imbalance between neuromodulators: gamma-aminobutyric acid (GABA) and glutamate. 
DBS leads to an increased activity of nigral GABAergic neurons and decreased activity of 
glutamate flow from the STN (Malhi and Sachdev, 2002; Piasecki and Jefferson, 2004). It is 
known, that dysfunction of these transmitters has been involved in psychiatric disorders 
(Drevets et al., 1997). Other possible explanation of post-DBS psychosis is the reduction 
or withdrawal of dopaminergic medication after the surgery (Voon et al., 2006). Finally, 
some researchers have seen a relation between post-DBS psychosis and pre-existing 
mental disturbances and have therefore stressed the importance of a thorough 
psychiatric assessment as a prerequisite for DBS surgery (Kalteis et al., 2006). We can 
hypothesize that psychiatric SAE in our study have multifactorial origin and could be 
explained by the fact, that older patients are less resistant to the surgical stress and their 
neuroplasticity is decreased, leading to a poorer ability to re-set the functional limbic 
circuit, affected by PD and DBS (Saint-Cyr et al., 2000). It should be noted that the STN is 
not the only possible target for DBS in the treatment of PD. In particular, DBS in the 
internal segment of the GPi has been found to be comparable to STN-DBS in terms of 
efficacy and safety (Honey et al., 2016). However, GPi-DBS has its own benefits and 
limitations (Groiss et al., 2009). Some centers favor the pallidal target for certain groups 
of patients (Okun et al., 2009). 
In the study IV, we found a statistically significant decline in the semantic category 
of VF in DBS patients at a median follow-up time of seven months after DBS surgery.  
A linear regression model showed a significant influence of age on this decline, but not 
of educational level, sex, disease duration, LED, disease progression and depression. We 
confirmed the findings of other research groups that VF declines in PD patients who 
undergo STN-DBS compared to PD patients who do not (Saez-Zea et al., 2012; Ehlen et al., 
2014; Smith et al., 2014). VF decline is reportedly the most common type of executive 
cognitive decline after DBS (De Gaspari et al., 2006; Weaver et al., 2009; Folett et al., 2010; 
York et al., 2008). Marshall et al. (2012) found lower VF at 6 months in a group of PD 
patients who underwent STN-DBS compared to a control group that did not. They 
hypothesized that VF deficits are caused by dysfunction in the striatum and in the 
interconnection in the striatum and the frontal lobe. Witt et al. (2008) found that DBS 
patients maintained cognitive functioning overall, but with a significant declines in VF 
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compared to patients given the “best medical treatment” without surgery; they concluded 
that concluded that impaired VF probably does not reflect disease progression alone but 
is, rather, an effect of DBS. Cilia et al. (2007) studied PD patients 12 months after DBS with 
SPECT employing the tracer 99mTc-ethyl cysteinate dimerbicisate to assess perfusion 
changes and their possible correlation with cognitive decline. Worsening fluency was 
associated with perfusion decrements in the left dorsolateral prefrontal cortex, the 
anterior portion of cingulate cortex, and the ventral caudate nucleus. A meta-analysis of 
28 studies, performed by Parsons et al. (2006) confirmed the decline in VF after STN-DBS. 
Only a few studies have addressed the question of a possible confounding effect of age on 
VF decline after STN-DBS in PD patients. The mechanism by which verbal frequency 
declines is unclear; one may hypothesize that dysfunction in the anterior cingulate region 
or in cortical—basal ganglionic circuits involved in the word retrieval process is involved. 
The effect of DBS on memory, if any, is inadequately known and still under investigation 
(Hershey et al., 2003). In the COMPARE trial Okun et al. (2009) compared the VF 
performance between PD patients with DBS to the STN and with DBS to the internal globul 
pallidus. The subjects were tested at seven months after surgery in four different 
conditions: with stimulation to the contacts providing optimal motor condition, ventral 
and dorsal to that, and in OFF-stimulation condition. A significant deterioration of VF was 
found in the STN group, this deterioration was persistent with stimulation OFF state. The 
authors suggested that VF decline is induced by surgery rather stimulation. Later, Mikos 
et al. (2011) tested this hypothesis by generating patient-specific computer models of the 
STN DBS subjects from the COMPARE trial. These models included co-registration of the 
pre-operative magnetic resonance images, computed tomography scans, a 3D brain atlas, 
neurophysiological microelectrode recodrings, DBS electrode and the volume of tissue 
activated (VTA) at the STN. Worsening of VF correlated with larger VTA in ventral regions 
of the STN, but better VF correlated with VTA in dorsal regions. These findings might be 
related to the theory of functional subregions of the STN, which states that the 
sensorimotor functions are attributed to the layers localized dorsolaterally, and 
associative functions – to the layers localized more centrally and ventrally. Stimulation of 
the ventral subregion of the STN might, therefore, cause VF decline. Additionally, the 
hypothesis of the “lead implantation effect” to verbal fluency impairment was assessed by 
Okun et al. (2012) in an open-label randomized controlled trial. In their trial patients with 
PD underwent STN-DBS with subsequent randomization to a group with immediate 
constant-current stimulation activation and a group with delayed (three months) 
activation. The verbal fluency performance, measured by the Delis-Kaplin executive 
function scale, worsened similarly in both groups at 3 months follow up after 
implantation. After activation of the stimulation this impairment did not worsen further 
in the group with delayed activation. In addition, at one year follow up the verbal fluency 
decline in both groups did not recover and remained similar.  
In the study V, we found that odour identification capacity was significantly lower 
in PD patients than in HC, and decrease of olfaction correlated with motor 
impairment in PD, with gait and axial rigidity.  
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The exact mechanism of the olfactory decline in PD is not fully clear; however, a 
detailed neuropathological staging concept was suggested by Braak et al. (2003). Studies 
in European (Verbaan et al., 2008) and in Chinese populations (Chen et al., 2015) showed 
that olfactory impairment is related to advanced age in PD patients. In the American 
population of older PD-free persons the progression of parkinsonian signs positively 
correlated with an impairment of olfaction (Wilson et al., 2008). However, normal ageing 
is also associated with olfactory decline (Murphy et al., 2002). We may speculate that 
olfactory decline is faster in PD than in HC. It may be related to alpha-synuclein 
depositions in the olfactory bulb (Ubeda-Banon et al., 2010) and/or atrophy of the limbic 
cortex (Wattendorf et al., 2009; Welge-Lüssen et al., 2009). Association of olfactory 
impairment and mobility parameters may be explained by the projections from the 
olfactory tracts to the orbitofrontal cortex and cerebellum (Doty 2003). The latter regions 
of the brain are involved in the processes of mobility and gait (Holtzer et al., 2014; Tian et 
al., 2017). Interestingly, in a Japanese study olfactory function in PD patients with 
akinetic-rigid form of the disease was significantly lower than in patients with tremor-
dominant and mixed forms (Iijima et al., 2011), and we also did not identify a significant 
correlation with tremor-related items of UPDRS-III. We may speculate that, in our study, 
the absence of association between olfaction and resting-state EEG may be partially 
explained by the fact, that the limbic system and olfactory bulbs are located deeper in the 
brain, thus electrical activity of their neurons cannot be properly registered as in the case 
of registration from the convexial cortex. Interestingly, in a cohort study, where the 
assessment of the olfactory function was combined with olfactory event-related 
potentials (OERP), a pattern of fluctuation of OERP was found over time (Meusel et al., 
2010). The authors stressed that the elicitation of OERP is dependent on the integrity of 
the transducing (from the amygdala to higher cortices) structures of the brain. A 
neurodegenerative process, such as PD, may disturb these structures, thus influencing the 
functional connection between olfactory and EEG recordings.  
Methodological considerations: strengths and limitations 
As a general remark, it is also important to note, that the present research was designed 
within the constraints of a timeline of a doctoral study and available resources. With 
regard to the study I: First, there is no common opinion regarding which certain markers 
can be used to predict cognitive decline in PD. By virtue of various fast developing 
methods and approaches, different research groups investigate different methods: 
spectral markers, connectivity markers  or their combination. In these conditions a 
thorough comparison of qEEG markers remains a challenge. However, future methods 
might further improve the validity of qEEG biomarkers of cognitive decline in PD. 
Second, criteria for the diagnosis of PD-MCI are changing over time (Ganguli et al., 2011; 
Petersen, 2004). In some studies a simple cognitive screening is performed using Mini-
Mental State Examination tool, in other cases a full cognitive assessment is performed 
with many cognitive tests. Since 2012 the Movement Disorders Society Task Force 
guidelines set a common criteria for PD-MCI (Litvan et al., 2012); however, the Diagnostic 
and Statistical Manual of Mental Disorders fifth edition has replaced the term MCI by 
"neurocognitive impairment" in 2013 (Simpson, 2014). 
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In sum, while differentiation between patients with PD with an intact cognitive state 
and patients with PD-D could be performed more or less clearly using qEEG markers, 
identification of the borderline level of cognition is relatively difficult. 
With regard to the study II, while it is important for practical reasons to identify strong 
risk factors for dementia developing within one or two years, the short mean observation 
period of three years is a limitation of the study, and a longer follow-up is warranted. 
Another limitation is the relatively small sample size. The strength of the study II is the 
comprehensive neuropsychological and psychiatric assessments performed in this study. 
High GRMP theta, especially when combined with poorer cognitive scores in “executive 
functions” and “working memory,” identifies patients with PD who are at a higher risk of 
progression to dementia. 
Some methological considerations of the study II should be also mentioned. First, the 
patients from the BASEL group were not very old, but still within the generally accepted 
age limits for the operation (Okun and Foote, 2010). Second, while the EARLYSTIM data 
reflects a multicenter research, our analysis reports the findings in one single center. 
However, single-center analyses have a role in planning and powering of subsequent 
larger studies (Bellomo et al., 2009). This report may serve as a starting point for research 
into age-dependent effects of DBS in PD. Finally, a detailed comparison of cognitive 
performance of the patients in the two groups is impossible based on available 
information in the EARLYSTIM report. In spite of this limitation, comparing both groups 
allows to estimate the influence of age on neuropsychiatric and neuropsychological 
outcome of DBS surgery in patients with PD. The apparently higher incidence of 
psychiatric complications after STN-DBS in older patients underscores the need for 
comprehensive pre- and postoperative psychiatric assessment in older DBS patients. 
However, the psychiatric SAE that arose in our patients (the BASEL group) were transient, 
occurring mainly in the early postoperative period. The benefits of DBS clearly 
outweighed its adverse effects in this group of patients. 
Some methodological considerations of the study IV should be noted. First, a 4- to 10-
month period between surgery and follow-up evaluation is relatively short. Future 
research with long-term assessment would provide further information regarding the 
correlation of STN-DBS and cognitive functioning. Second, the patients from our STN-DBS 
group were not assessed in the ‘OFF’ stimulation condition; VF executive decline has been 
reported also in the ‘OFF’ stimulation state. Third, our small sample size limits the type of 
statistical analyses and the generalizability of our findings. Fourth, and perhaps most 
importantly, this was not a randomized study. DBS was performed or not performed 
according to clinical indications alone. The two groups of patients in the study were thus 
not comparable at baseline, in the important sense that all patients in the first group, but 
none in the second group, had been judged to be candidates for DBS on the basis of 
standardized clinical criteria. We therefore cannot be sure that the observed decline in VF 
was truly the result of DBS surgery or age itself. In spite of these limitations, our finding 
of a significant decline in the semantic category of VF in this relatively small sample 
highlights the sensitivity of this test for detecting cognitive changes after STN-DBS. We 
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found that the risk of VF decline after DBS surgery is greater the older the patients.  At 
present, there is no precise age cut-off for DBS surgery. Studies in larger groups of patients 
for longer periods of observation are needed to determine whether the VF decline that is 
seen on relatively early follow-up might be a predictor of long-term cognitive 
performance in PD patients treated with STN-DBS. A screening tool with age-related cut-
off values should be developed. 
Finally, some methodological considerations of the study V should be mentioned. 
Firstly, the «Screening 12 Test» means «forced» selection of one correct odour of four on 
each of the 12 cards; thus there is  a theoretical 25% chance of random selection of the 
correct answer. In this regard, a larger comprehensive olfactory test battery would allow 
a more precise identification of the level of hyposmia. Secondly, the UPDRS-III tool 
comprises a separate bilateral motor assessment, but the olfactory test which we applied 
assessed olfaction in both nostrils at the same time. An analysis of the association between 
sides of olfactory and motor impairment would be interesting. Lastly, a selection bias may 
be present because of the single-site cross-sectional setting of our study. Studies with 
larger samples and multiple centres could overcome this limitation.  
A final important issue regarding all studies in this work concerns the possible effects 
of antiparkinsonian medication on cognitive symptoms within PD. It should be 
mentioned, that we statistically checked such effects with regression models (LEDD 
introduced as predictor in the models). We may speculate that antiparkinsonian 
medication has little, if such, effects on cognition in PD (as previously suggested by some 
colleagues, e.g. Stam 2010; George et al., 2013) or that all patients in this work were in 
optimal medicated state. In the present studies all patients reported to be stable on their 
medication, patients who received anticholinergic drugs were not present in the sample. 
In this work, this issue was also discussed (Chapter 3. Influence of dopamine-replacement 
therapy on qEEG parameters). 
Conclusions  
Study I 
In sum, changes in spectral powers, delta and theta, have the highest significance to 
discriminate between PD-D and dementia-free patients with PD, while changes in spectral 
powers, theta and alpha, have the highest significance to separate MCI from normal 
cognition in PD. Findings regarding discrimination between MCI and dementia in PD are 
less consistent within reports, though delta and beta powers showed good discriminative 
capacity. With regard to connectivity measures, PLI has the highest significance to 
discriminate between PD-D and nondemented patients with PD.  
Study II 
Patients who manifest a decrease in cognitive tasks: executive functions and working 
memory, and increase of global median relative theta power, should be targeted for future 
early therapeutic intervention and disease modification. Perhaps, a combination of 
neurocognitive tests with qEEG improves identification of patients with PD and higher 
risk of cognitive decline.  
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Study III 
The higher incidence of STN-DBS-related psychiatric complications underscores the 
need for comprehensive psychiatric pre-and post operative assessment in older DBS 
candidates. However, these psychiatric SAE were transient, and the benefits of DBS clearly 
outweighed its adverse effects.  
Study IV 
A significant decline in the semantic category of verbal fluency in this relatively 
highlights the sensitivity of verbal fluency testing for detecting cognitive changes after 
STN-DBS. Studies in larger groups of patients for longer periods of observation are needed 
to determine verbal fluency decline might be a predictor of long-term cognitive 
performance in PD patients treated with STN-DBS. 
Study V 
Because an olfactory decrease in PD correlates with motor impairment (especially axial 
signs), the assessment of olfactory function may be a useful additional tool in the detection 
and follow-up of PD, and may have a possible relation with the cognitive outcome at long-
term follow-up. 
General conclusion and future directions 
The detection of cognitive impairment associated with PD is of upmost importance for 
future generations in terms of prevention of morbidity and mortality, social care and 
healthcare costs. Biomarkers that could identify PD patients with a risk of progression to 
PD-D early in the course of PD would potentially contribute towards the identification of 
novel treatment options. Future studies should involve the longitudinal assessment of 
participants (perhaps, longer than 5 years), to determine whether there is a relation 
between the increase of the EEG power of slow frequency waves, the severity of initial 
olfactory decline, gait impairment, and STN-DBS with cognitive decline, and whether the 
PD patients with abovementioned factors are associated with a more rapid cognitive 
decline and/or PD-D.  
 
The heterogeneity of cognitive decline in PD means that is it unlikely a single biomarker 
will predict dementia risk, and hence, a composite biomarker is a realistic goal. It is 
important to stress, that each of the components of such composite biomarker should not 
bear similar information with regard to cognitive prediction, in other words: should not 
correlate between each other, but should reflect particular features of the cognitive 
course in PD. Importantly, changes of such markers should precede the clinical 
manifestation of cognitive decline in PD. Thus, these markers may become a valuable aid 
for timely selection of patients prone to pharmacological and nonpharmacological 
interventions of prevention at a very early stage of PD and thereby potentially improve 
clinical results. Prospective studies with larger cohorts investigating topographical scalp 
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distribution of qEEG changes as well as connectivity and its association with cognitive 
decline in PD are warranted.  
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